

No. 03-724

IN THE
Supreme Court of the United States

F. Hoffmann-La Roche, Ltd., et al.,
Petitioners,

v.

Empagran, S.A., et al.

On Writ of Certiorari
to the United States Court of Appeals
for the District of Columbia Circuit

BRIEF FOR RESPONDENTS

Michael D. Hausfeld
Paul T. Gallagher
Brian A. Ratner
COHEN, MILSTEIN,
HAUSFELD & TOLL, P.L.L.C.
1100 New York Ave., N.W.
Suite 500, West Tower
Washington, DC 20005

Thomas C. Goldstein
(Counsel of Record)
Amy Howe
GOLDSTEIN & HOWE, P.C.
4607 Asbury Place, N.W.
Washington, DC 20016
(202) 237-7543

Michael H. Gottesman
600 New Jersey Ave., N.W.
Washington, DC 20001

March 15, 2004

QUESTIONS PRESENTED

1. Whether the Foreign Trade Antitrust Improvements Act narrows the Sherman Act's application over the claims of foreign purchasers of a worldwide cartel that has direct, substantial, and foreseeable effects on U.S. commerce.

2. Whether overseas purchasers of a worldwide cartel that is prohibited by the antitrust laws have suffered "antitrust injury" and have "antitrust standing."

RULE 29.6 STATEMENT

Respondent Empagran has no parent companies, and no publicly held companies have a 10% or greater ownership interest in Empagran.

Respondent Nutricion has no parent companies, and no publicly held companies have a 10% or greater ownership interest in Nutricion.

Respondent Windridge is the business name for the business owned and operated in partnership by Cynray Pty. Ltd. and Larkray Pty. Ltd. Both of these companies are proprietary limited companies, all of the shares of which are held by natural persons.

Respondent Stirol has no parent companies, and no publicly held companies have a 10% or greater ownership interest in Stirol.

Brisbane Export Corp. was a respondent at the certiorari stage but has since withdrawn from the case.

TABLE OF CONTENTS

QUESTIONS PRESENTED	i
RULE 29.6 STATEMENT	ii
TABLE OF CONTENTS	iii
TABLE OF AUTHORITIES	v
BRIEF FOR THE RESPONDENTS	1
RELEVANT STATUTORY PROVISIONS	1
STATEMENT OF THE CASE	1
SUMMARY OF THE ARGUMENT	3
ARGUMENT.....	5
I. Because Global Cartels’ Domestic And Foreign Effects Are Inextricably Intertwined, Respondents Prevail Even Under Petitioners’ Construction of The FTAIA And Foreign Plaintiffs’ Claims Against Such Cartels Furthermore Directly Advance U.S. Interests.....	9
A. The Market for Bulk Vitamins Is a Global Market. ...	10
B. The Effects Of Petitioners’ Conduct On U.S. Commerce Gave Rise To Respondents’ Claims.....	11
C. U.S. Interests Are Directly Advanced By Recognizing The Claims Of All Victims Of An Integrated Cartel That Operates In The United States.....	13
II. The FTAIA’s Jurisdictional Limitation Does Not Apply To Conduct Involving Import Commerce And Thus Does Not Apply To Worldwide Cartels.....	19
A. The FTAIA Limits The Scope Of The Sherman Act Solely In Cases Involving Only U.S. Export Commerce.....	19
B. The Authorities Cited By Petitioners Actually Support <i>Respondents’</i> Reading Of The FTAIA.....	23
III. Congress Inserted Clause 2 Merely To Ensure That The Covered Foreign Conduct Must Have An <i>Anti- Competitive</i> Impact On Domestic Commerce To Be Actionable Under The Sherman Act.	25

A.	The Drafting History, Text, And Structure Of The FTAIA Confirm Congress’s Intent To Adopt The <i>National Bank of Canada</i> Rule.....	27
B.	The House Report On Which Petitioners Rely Confirms That Congress Intended To Preserve The Claims Of Overseas Purchasers.....	31
IV.	As Direct Victims Of Petitioners’ Worldwide Cartel, Respondents Have Suffered “Antitrust Injury” And Have “Antitrust Standing.”	35
A.	Respondents Have Antitrust Standing Even Under Petitioners’ Proposed Standards.	36
B.	Petitioners’ Proposed Standing Rule Is Inconsistent With This Court’s Precedents And Congress’s Intent.	37
1.	Respondents Satisfy The Settled Requirements For Antitrust Standing.....	37
2.	Congress Declined To Adopt The Restriction On Standing That Petitioners Propose.	41
V.	The Other Arguments Of Petitioners’ <i>Amici</i> Lack Merit.....	44
A.	The Government’s Leniency Program Is Not A Justification for Misinterpreting the FTAIA.....	44
B.	The Exercise Of Jurisdiction Over A Worldwide Cartel Does Not Offend Comity.....	47
	CONCLUSION.....	50

TABLE OF AUTHORITIES

Supreme Court Cases

<i>Associated Gen. Contractors v. Cal. State Council of Carpenters</i> , 459 U.S. 519 (1983)	38
<i>Atl. Richfield Co. v. USA Petro. Co.</i> , 495 U.S. 328 (1990)	37
<i>Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc.</i> , 429 U.S. 477 (1977)	37
<i>Cargill, Inc. v. Monfort</i> , 479 U.S. 104 (1986)	37
<i>Cont'l Ore Co. v. Union Carbide & Carbon Corp.</i> , 370 U.S. 690 (1962)	13
<i>Hanover Shoe, Inc. v. United Shoe Mach. Corp.</i> , 392 U.S. 481 (1968)	40
<i>Hartford Fire Ins. Co. v. California</i> , 509 U.S. 764 (1993)	4, 5, 6, 7, 20, 22, 47
<i>Illinois Brick Co. v. Illinois</i> , 431 U.S. 720 (1977)	40
<i>Jefferson Parish Hosp. No. 1 v. Hyde</i> , 466 U.S. 2 (1984)	30
<i>John Hancock Mut. Life Ins. Co. v. Harris Trust & Sav. Bank</i> , 510 U.S. 86 (1993)	30
<i>Kansas v. Utilicorp United Inc.</i> , 497 U.S. 199 (1990)	40
<i>Lauritzen v. Larsen</i> , 345 U.S. 571 (1953)	47
<i>Matsushita Electrical Industries v. Zenith Radio Corp.</i> , 475 U.S. 574 (1986)	8, 25, 42
<i>McCulloch v. Sociedad Nacional de Marineos de Honduras</i> , 372 U.S. 10 (1963)	47
<i>McLain v. Real Estate Bd.</i> , 444 U.S. 232 (1980)	38
<i>Pfizer Inc. v. Government of India</i> , 434 U.S. 308 (1978)	3, 14, 15, 30, 32, 36, 39, 43
<i>Romero v. International Terminal Operating Co.</i> , 358 U.S. 354 (1958)	47
<i>Strassheim v. Daily</i> , 221 U.S. 280 (1911)	34
<i>Summit Health, Ltd. v. Pinhas</i> , 500 U.S. 322 (1991)	7, 38
<i>Tampa Elec. Co. v. Nashville Coal Co.</i> , 365 U.S. 320 (1961)	10

<i>Timken Roller Bearing Co. v. United States</i> , 341 U.S. 593 (1951)	8
<i>United States Indus./Fed. Sheet Metal v. Director</i> , 455 U.S. 608 (1982)	12
<i>United States v. American Tobacco Co.</i> , 221 U.S. 106 (1911)	3, 7
<i>United States v. Borden Co.</i> , 347 U.S. 514 (1954).....	44
<i>United States v. National Lead Co.</i> , 332 U.S. 319 (1947).....	8
<i>Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko</i> , 124 S. Ct. 872 (2004).....	17

Lower Court Cases

<i>Animal Sci. Prods. v. Chinook Group</i> , Misc. No. 99-197, MDL 1285 (TFH).....	11
<i>Ballard v. Savage</i> , 65 F.3d 1485 (CA9 1995)	13
<i>Den Norske Stats Oljeselskap AS v. Heeremac v.o.f.</i> , 241 F.3d 420, 435 (CA5 2001).....	12, 13, 19, 22, 25, 30, 35, 39
<i>Dominicus Americana Bohio v. Gulf & Western Indus., Inc.</i> , 473 F. Supp. 680 (S.D.N.Y. 1979)	42
<i>Ferromin Int'l Trade Corp. v. Ucar Int'l, Inc.</i> , C.A. No. 99-693 (E.D. Pa.).....	39
<i>Hamilton v. United Healthcare of La.</i> , 310 F.3d 385 (CA5 2002).....	13
<i>Hunt v. Mobil Oil Corp.</i> , 550 F.2d 68 (CA2), cert. denied, 434 U.S. 984 (1977)	42
<i>Industria Siciliana Asfalti, Bitumi, S.p.A. v. Exxon Research & Engineering Co.</i> , No. 75-5828-CSH, 1977 U.S. Dist. LEXIS 17851 (S.D.N.Y. Jan. 18, 1977).....	42
<i>Kruman v. Christie's Int'l PLC</i> , 284 F.3d 384 (CA2 2002).....	25, 29, 30, 33, 39
<i>Lanier v. Am. Bd. of Endodontics</i> , 843 F.2d 901 (CA6 1988).....	13
<i>Latinoquimici-Amtex S.A. v. Akzo Nobel Chems. B.V.</i> , No. 03-CV-10312 (S.D.N.Y.)	39
<i>Mannington Mills, Inc. v. Congoleum Corp.</i> , 595 F.2d 1287 (CA3 1979).....	6

<i>National Bank of Canada v. Interbank Card Ass'n</i> , 666 F.2d 6 (CA2 1981).....	25, 26, 27, 29, 31
<i>Newco Trading Co. v. Ajinomoto Co., Inc. et al.</i> , No. 03-CV-8217 (S.D.N.Y.).....	39
<i>Pacific Seafarers, Inc. v. Pacific Far East Line, Inc.</i> , 404 F.2d 804 (CA9 1968).....	34
<i>SFH, Inc. v. Millard Refrigerated Servs.</i> , 339 F.3d 738 (CA8 2003).....	13
<i>United States v. Aluminum Co. of America</i> , 148 F.2d 416 (CA2 1945).....	7
<i>United States v. Rockford Mem. Corp.</i> , 898 F.2d 1278 (CA7 1990).....	10
<i>United States v. Wright-Barker</i> , 784 F.2d 161 (CA3 1986).....	7
<i>Vitamins Antitrust Litig., In re.</i> , Misc. No. 99-197 (D.D.C. Feb. 18, 2004).....	46
<i>Williams v. Imhoff</i> , 203 F.3d 758 (CA10 2000).....	13

Statutes

15 U.S.C. 1.....	37
15 U.S.C. 15(a).....	2, 35
15 U.S.C. 15(b).....	30, 43
Foreign Trade Antitrust Improvements Act of 1982, Pub. L. No. 97-290, 96 Stat. 1246, codified at	
15 U.S.C. 6a.....	passim
15 U.S.C. 6a(1).....	29, 30, 34
15 U.S.C. 6a(1)(A).....	21
15 U.S.C. 6a(1)(B).....	21
15 U.S.C. 6a(2).....	passim
proviso.....	4, 20, 21, 23, 29, 30, 43

FTAIA Legislative History

Foreign Trade Antitrust Improvements Act, H.R. 5235, 97th Cong. (1982).....	27, 28
<i>Foreign Trade Antitrust Improvements Act: Hearings on H.R. 2326 Before the Subcomm. on Monopolies and</i>	

<i>Commercial Law of the House Comm. on the Judiciary,</i> 97th Cong. (1981).....	7, 27, 28, 37
H.R. REP. NO. 97-686 (1982), <i>reprinted in</i> 1982 U.S.C.C.A.N. 2487.....	4, 21, 24, 27, 31, 32, 33, 34, 42, 43, 45
S. CONF. REP. NO. 97-644 (1982)	45
<i>The Foreign Trade Antitrust Improvements Act: Hearings</i> <i>on S. 795 Before the Comm. on the Judiciary, 97th</i> Cong. (1981).....	28
128 Cong. Rec. 18,953 (1982) (Rep. McClory)	21, 25, 31
128 Cong. Rec. 18,953 (1982) (Rep. Rodino).....	3
U.S. Government -- D.O.J. Enforcement Guidelines	
U.S. D.O.J., <i>Antitrust Enforcement Guidelines for</i> <i>International Operations</i> (1995)	22
U.S. D.O.J., <i>Antitrust Guide for International Operations</i> (Jan. 26, 1977)	22
U.S. Government -- D.O.J. Speeches	
Barnett, Belinda A., Sr. Counsel to the Ass't A.G., Antitrust in the Twenty-First Century – “Status Report on International Cartel Enforcement,” Address Before the State Bar of Georgia Antitrust Law Section (Nov. 30, 2003).....	9
Griffin, James M., Dep. Ass't A.G., An Inside Look at a Cartel at Work: Common Characteristics of International Cartels, Address Before the A.B.A. Section of Antitrust Law 48th Annual Spring Meeting (Apr. 6, 2000), <i>available at</i> http://www.usdoj.gov/atr/public/speeches/4489.pdf	16, 46
Griffin, James M., Dep. Ass't A.G., Key Challenges in Public Enforcement Against International Cartels, Address Before the British Inst. of Int'l & Comparative Law Second Ann. Conf. on Int'l and Comparative Competition Law: Trends and Tensions (May 2002).....	16, 17
Griffin, James M., Dep. Ass't A.G., The Modern Leniency Program After Ten Years: A Summary Overview of the Antitrust Division's Criminal Enforcement Program, Presentation Before the A.B.A. Antitrust	

Section (Aug. 12, 2003), <i>available at</i> http://www.usdoj.gov/atr/public/speeches/201477.htm	46
Hammond, Scott D., Dir. of Crim. Enf., D.O.J. Antitrust Div., Lessons Common to Detecting and Deterring Cartel Activity, Address Before the 3rd Nordic Competition Policy Conference (Sept. 12, 2000), <i>available at</i> http://www.usdoj.gov/atr/public/speeches/6487.pdf	17, 46
Hammond, Scott D., Dir. of Crim. Enf., D.O.J. Antitrust Div., When Calculating the Costs and Benefits of Applying for Corporate Amnesty, How Do You Put a Price Tag on an Individual's Freedom?, Address at the Fifteenth Ann. Nat'l Inst. of White Collar Crime (Mar. 8, 2001).....	47
James, Charles A., Ass't A.G., International Antitrust in the 21st Century: Cooperation and Convergence, Address before the OECD Global Forum on Competition (Oct. 17, 2001).....	19
Klein, Joel I., Ass't A.G., International Anti-Cartel Enforcement (Sept. 30, 1999).....	1
Kolasky, William J., Dep. Ass't A.G., U.S. and EU Competition Policy: Cartels, Mergers, and Beyond, Address Before the Council for the United States and Italy Bi-Annual Conference (Jan. 25, 2002), <i>available</i> <i>at</i> http://www.usdoj.gov/atr/public/speeches/9848.pdf ...17, 18	
Pate, R. Hewitt, Acting Ass't A.G., Anti-Cartel Enforcement, Address Before the British Inst. of Int'l and Comparative Law Third Ann. Conf. on Int'l and Comparative Competition Law (May 16, 2003), <i>available at</i> http://www.usdoj.gov/atr/public/speeches/201199.htm	47
Spratling, Gary R., Dep. Ass't A.G., International Cartels: The Intersection Between FCPA Violations and Antitrust Violations, Address Before the American Conference Institute 7th National Conference on Foreign Corrupt Practices Act (Dec. 9, 1999).....	1

Stark, Charles S., Chief Foreign Commerce Section, Recent International Antitrust Developments, Remarks Before the World Trade Institute Seminar on Advanced International Antitrust Practices and Related Trade Issues (Dec. 5, 1983).....	26
---	----

Legislative Proposals

Foreign Trade Antitrust Improvements Act of 1985, S. 397, 99th Cong. (1985).....	30, 43
<i>Foreign Trade Antitrust Improvements Act of 1985: Hearings on S. 397 Before the Comm. on the Judiciary, 99th Cong. (1985).....</i>	30, 43, 44
Foreign Trade Antitrust Improvements Act of 1986, S. 2164, 99th Cong. (1986).....	30, 43
Foreign Trade Antitrust Improvements Act of 1989, S. 50, 101st Cong. (1989).....	30, 43
H.R. 1086, tit. II, § 213(a), 108th Cong. (2003).....	44

Treatises

AREEDA, PHILLIP E., ET AL., ANTITRUST LAW: AN ANALYSIS OF ANTITRUST PRINCIPLES AND THEIR APPLICATION	16, 20, 21, 23, 26, 35, 38
FUGATE, WILBUR L., FOREIGN COMMERCE AND THE ANTITRUST LAWS (5th ed. 1996).....	26
HAWK, BARRY E., UNITED STATES, COMMON MARKET AND INTERNATIONAL ANTITRUST (2d ed. 1985 & Supps.).....	24, 25, 26, 39
POSNER, RICHARD A., ANTITRUST LAW (2d ed. 2001)	12
POSNER, RICHARD A., ECONOMIC ANALYSIS OF THE LAW (1st ed. 1972).....	16
RESTATEMENT (THIRD) OF FOREIGN RELATIONS LAW OF THE UNITED STATES (1987).....	6, 7, 20, 21, 48, 49, 50
WALLER, SPENCER WEBER, ANTITRUST AND AMERICAN BUSINESS ABROAD (3d ed. 1997 & Supp. 2002)	15, 26, 32

Books

CONNOR, JOHN M., GLOBAL PRICE FIXING: OUR CUSTOMERS ARE THE ENEMY (2001)	14, 50
---	--------

First, Harry, <i>Evolving Toward What? The Development of International Antitrust, in THE FUTURE OF TRANSNATIONAL ANTITRUST LAW</i> (Josef Drexler ed., 2003).....	16
Jenny, Frédéric, Vice Chairman, Conseil de la concurrence; Chairman, OECD Competition Law and Pol’y Comm.; Chairman, WTO Working Group on the Interaction Between Trade and Competition Pol’y, <i>Globalization, Competition and Trade Policy: Convergence, Divergence and Cooperation, in COMPETITION POLICY IN THE GLOBAL TRADING SYSTEM</i> (Clifford A. Jones & Mitsuo Matsushita eds., 2002).....	18
JOELSON, MARK R., AN INTERNATIONAL ANTITRUST PRIMER (2001)	24
MIROW, KURT RUDOLF & MAURER, HARRY, WEBS OF POWER: INTERNATIONAL CARTELS AND THE WORLD ECONOMY (1982)	46
NANDA, VED P. & PANSIUS, DAVID K., LITIGATION OF INTERNATIONAL DISPUTES IN U.S. COURTS (2003)	11
OECD, HARD CORE CARTELS (2002).....	17
Shenefield, John H., <i>The Perspective of the U.S. Department of Justice, in PERSPECTIVES ON THE EXTRATERRITORIAL APPLICATION OF U.S. ANTITRUST AND OTHER LAWS</i> (Joseph P. Griffin ed., 1979).....	23
Unger, Sherman E., <i>The Role of the Commerce Department, in THE EXPORT TRADING COMPANY ACT OF 1982</i> (Joseph P. Griffin ed., 1982).....	20
Law Review Articles	
Areeda, Phillip, <i>Antitrust Violations Without Damage Recoveries</i> , 89 HARV. L. REV. 1127 (1976).....	16
Brilmayer, Lea & Norchi, Charles, <i>Federal Extraterritoriality and Fifth Amendment Due Process</i> , 105 HARV. L. REV. 1217 (1992)	35
Bruce, John F. & Pierce, John C., <i>Understanding the Export Trading Company Act and Using (Or Avoiding) Its Antitrust Exemptions</i> , 38 BUS. LAW. 975 (1983).....	26

Davis, Ronald R., <i>International Cartel and Monopolization Cases Expose a Gap in Foreign Trade Antitrust Improvements Act</i> , ANTITRUST, Summer 2001.....	14
First, Harry, <i>The Vitamins Case</i> , 68 ANTITRUST L.J. 711 (2001)	40
Fox, Eleanor M., <i>International Antitrust and the Doha Dome</i> , 43 VA. J. INT'L L. 911 (2003).....	7
Gill, David, <i>Review of Antitrust and American Business Abroad</i> , 77 AM. J. INT'L L. 679 (1983).....	23
Hawk, Barry E., <i>International Antitrust Policy and the 1982 Acts: The Continuing Need for Reassessment</i> , 51 FORDHAM L. REV. 201 (1982).....	21, 26
Hawk, Barry E., <i>Special Defenses and Issues</i> , 50 ANTITRUST L.J. 559 (1981).....	8
<i>Interview with Gary Spratling</i> , ANTITRUST, Summer 2000, at 11	47
Rahl, James A., <i>American Antitrust and Foreign Operations: What is Covered?</i> , 8 CORNELL INT'L L.J. 1 (1974)	25
Shenefield, John H., <i>Thoughts on Extraterritorial Application of the United States Antitrust Laws</i> , 52 FORDHAM L. REV. 350 (1983)	26
Spratling, Gary, <i>Cartel Roundtable, The Architects of Enforcement</i> , 6 GLOBAL COMPETITION REV. 25 (2003).....	47
Victor, A. Paul & Chou, John G., <i>United States Antitrust Jurisdiction Over Overseas Disputes After Title IV of the 1982 Export Trading Company Act and Timberlane</i> , 10 FORDHAM INT'L L.J. 1 (1986).....	26
Waller, Spencer Weber, <i>Bringing Globalism Home: Lessons from Antitrust and Beyond</i> , 32 LOY. U. CHI. L.J. 113 (2000)	48
Weintraub, Russell J., <i>Globalization's Effect on Antitrust Law</i> , 34 NEW ENG. L. REV. 27 (1999)	49
Zarin, Donald, <i>The Export Trading Company Act: Reducing Antitrust Uncertainty in Export Trade</i> , 17 GEO. WASH. J. INT'L L. & ECON. 297 (1983)	26

Other Journal Articles

- Wils, Wouter P.J., *Does the Effective Enforcement of Articles 81 and 82 EC Require Not Only Fines on Undertakings But Also Individual Penalties, In Particular Imprisonment?* (2001), available at <http://www.iue.it/RSCAS/Research/Competition/2001/Wils.pdf>16
- Woods, Donncaadh, *Private Enforcement of Antitrust Rules* (presented at Loyola Univ. Chicago, Inst. for Consumer Antitrust Stud., Feb. 20, 2004)18

Foreign Materials

- Max Boegl Bauunternehmung v. Hanson Germany*, Judgment of the Berlin Landgericht of 27 June 200318
- Provimi v. Aventis Animal Nutrition SA*, [2003] E.C.C. 29.....50

Other

- Int'l Comp. Pol'y Adv. Comm., Final Rep't to the A.G. (2000)17, 46
- Plea Agreement, *United States v. F. Hoffmann-La Roche, Ltd.*, No. 3:99-CR-00184 (filed May 20, 1999)2
- U.S. D.O.J., Press Release, Department of Justice, F. Hoffman-La Roche and BASF Agree to Pay Record Criminal Fines for Participating in International Vitamin Cartel (May 20, 1999)1

BRIEF FOR THE RESPONDENTS

Respondents Empagran, S.A., et al., respectfully request that the judgment of the United States Court of Appeals for the D.C. Circuit be affirmed.

RELEVANT STATUTORY PROVISIONS

The relevant statutory provisions are reproduced in the Appendix, *infra*, at 1a-2a.

STATEMENT OF THE CASE

1. Petitioners are more than twenty U.S. vitamin producers and distributors and their foreign affiliated companies. J.A. 19-33. Together, they perpetrated “the most pervasive and harmful criminal antitrust conspiracy ever uncovered.” Joel I. Klein, Ass’t A.G., Speech of Sept. 30, 1999, at 5.¹ This conspiracy – which petitioners named “Vitamins, Inc.” – was a “textbook example” of a worldwide cartel. Gary R. Spratling, Dep. Ass’t A.G., Speech of Dec. 9, 1999, at 13. By allocating geographic markets amongst themselves and fixing prices, petitioners successfully eliminated competition in the sale of bulk vitamins, reaching agreements “on everything from how much product each company would produce, which customers they would sell it to, and at what price they would sell it.” *Ibid*.

The U.S. government’s prosecution of petitioners was the crowning achievement of its aggressive pursuit of international cartels in the mid-1990s. Contrary to petitioners’ claim that they were charged with “fixing prices of vitamins sold in the United States” (Br. 4), in fact, they were prosecuted here for their “*worldwide* conspiracy to raise and fix prices and allocate market shares for certain vitamins sold in the United States *and elsewhere*” (U.S. D.O.J., Press Release, Department of Justice, F. Hoffman-La Roche and BASF Agree to Pay Record Criminal Fines for Participating in International Vitamin Cartel (May 20, 1999) (emphases added)). Petitioners were indicted for, and

¹ The Table of Authorities provides detailed information on where this and other government speeches are available.

pled guilty to, “a combination and conspiracy to suppress and eliminate competition by fixing the price and allocating the volume of certain vitamins manufactured and sold in the United States *and elsewhere*.” Plea Agreement, *United States v. F. Hoffmann-La Roche, Ltd.*, No. 3:99-CR-00184 (May 20, 1999).

This suit was filed against petitioners by Procter & Gamble (a U.S. corporation), six of its U.S. and foreign affiliated companies, and foreign companies (respondents here), all of which purchased bulk vitamins “for delivery outside the United States” during the period of the cartel. J.A. 17-19, 58.² They sued petitioners in the District Court for the District of Columbia under, *inter alia*, Section 4 of the Clayton Act, which confers a private right of action upon persons “injured in [their] business or property by reason of anything forbidden in the antitrust laws.” 15 U.S.C. 15(a). The complaint was designated a companion case to ongoing litigation brought by persons who purchased bulk vitamins for delivery in this country.

2. Petitioners moved to dismiss. Notably, they did not invoke doctrines such as comity, conflict of laws, or *forum non conveniens* to show that, assuming jurisdiction exists, the courts should decline to *exercise* that jurisdiction. Instead, they contended that (i) the complaint was subject to the Foreign Trade Antitrust Improvements Act of 1982 (FTAIA), Pub. L. No. 97-290, 96 Stat. 1246 (codified at 15 U.S.C. 6a) and was barred by FTAIA Clause 2’s requirement that the effect of the defendants’ conduct on U.S. commerce “give rise to a claim under” the Sherman Act; and (ii) respondents lacked standing. The district court agreed with the former contention and did not reach the latter. Pet. App. 48a-52a.

The D.C. Circuit reversed. Pet. App. 1a-39a. The court agreed with the Second Circuit and Judge Patrick Higginbotham (dissenting in the Fifth Circuit) that Clause 2 does not require that “the plaintiff’s claim” arise from the effect of the defendants’ conduct on U.S. commerce. See Pet. App. 17a-20a. It therefore did not reach respondents’ contention that the adverse

² The claims of the Procter & Gamble parties have been held in abeyance during this appeal. J.A. 69.

effect of petitioners' cartel on U.S. commerce did, in fact, give rise to their claims. *Id.* 3a. The court also concluded that respondents have standing to sue. *Id.* 33a-37a.

SUMMARY OF THE ARGUMENT

In enacting the FTAIA, Congress acted against the backdrop of long-settled precedents applying the Sherman Act. A line of this Court's decisions dating back to *United States v. American Tobacco Co.*, 221 U.S. 106 (1911), holds that the Sherman Act bars anti-competitive conspiracies with substantial effects on U.S. commerce, and furthermore extends to the activities here *and abroad* in furtherance of such conspiracies. Petitioners' cartel was illegal under this settled law.

The "effects test" rests on the recognition that the United States may be seriously harmed by anti-competitive activities abroad. And, as this Court concluded in *Pfizer Inc. v. Government of India*, 434 U.S. 308, 315 (1978), absent liability to foreign plaintiffs, the perpetrators of a global conspiracy will use their profits abroad to compensate for the risk of punishment in this country. Bulk vitamins, in particular, are traded freely between geographic regions; in a competitive market, purchasers will buy wherever prices are lowest. There is therefore no "U.S. market" for bulk vitamins, but instead a global market.

In light of the foregoing, jurisdiction exists in this case for three independent reasons. First, even if petitioners' interpretation of the FTAIA were correct, respondents would satisfy it. Petitioners argue that in the FTAIA Congress excluded conduct affecting U.S. commerce from the Sherman Act unless those U.S. effects "give rise to" the plaintiff's claim. But the effect of petitioners' cartel on U.S. commerce *did* "give rise to" respondents' injuries. Petitioners stopped overseas purchasers such as respondents from buying bulk vitamins here, or from intermediaries who purchased here. Furthermore, had competitive conditions existed in this country, the cartel would have collapsed everywhere as a result of arbitrage.

Second, the FTAIA does not restrict the antitrust laws' application to global cartels. That statute defines the scope of the Sherman Act – *i.e.*, the conduct that the Sherman Act prohibits –

rather than the standing of private parties to sue. And it limits the Sherman Act *only* with respect to foreign commerce “other than import trade or import commerce” (15 U.S.C. 6a); likewise, its proviso limiting standing applies solely to conduct that only affects U.S. export commerce (*id.*, proviso). The FTAIA therefore applies only to *export* commerce (see *Hartford Fire Ins. Co. v. California*, 509 U.S. 764, 798 (1993)) and not to cartels, which directly involve U.S. domestic and import commerce.

Third, even if the FTAIA did apply here, it would not impose the requirement petitioners propose. Clause 2, which is not a standing provision, does not require that the plaintiff’s own injury arise from the effect of the defendants’ conduct on U.S. commerce. Instead – as the United States, every antitrust treatise, and every other contemporaneous commentator recognized, and as the legislative history makes clear – Congress adopted Clause 2 merely to provide that the Sherman Act does not apply to conduct that has a *pro*-competitive effect in this country.

Petitioners’ contrary reading rests on parts of three sentences in one House Report. H.R. REP. NO. 97-686 (1982), *reprinted in* 1982 U.S.C.C.A.N. 2487 (House Report) (reproduced in App., *infra*). Legislative history that thin would not justify holding that Congress abandoned a century of precedent even if that Report addressed Clause 2 as finally enacted, but it did not. Even more important, in context, those quotations actually show that Congress intended to *reaffirm* the right of persons injured overseas to sue in U.S. courts.

Petitioners’ “antitrust injury” and “antitrust standing” arguments, which mirror their jurisdictional arguments, are equally meritless. Those prudential doctrines seek to identify the most efficient enforcers of the antitrust laws; they do not create gaps immunizing unlawful activity from suit. Respondents are the prototypical enforcers of the antitrust laws; they are direct purchasers injured by the anti-competitive effects of petitioners’ unlawful conduct, and their claims deter cartel activities that directly harm U.S. interests. Nor are cases like this one unmanageable; they are litigated together with the indistinguishable claims of domestic purchasers and require no special inquiries into foreign economic conditions because they allege *per se*

antitrust violations. Congress moreover declined in the FTAIA and afterwards to overrule decisions holding that a plaintiff's injury need *not* arise from the effects of anti-competitive activity on the United States.

Nor is there merit to the two remaining arguments advanced by petitioners' *amici*. First, the government's antitrust leniency program has no bearing on the questions presented, not least because it was adopted in all relevant respects well after Congress enacted the FTAIA. Pending legislation will limit the civil liability of leniency program participants, whereas the government's argument illogically would limit the exposure of companies that do *not* participate. And the government has in the past rightly disparaged precisely the argument it makes now. Worst, the government ignores that Clause 2 defines the *scope* of the Sherman Act, rather than the *standing* of private parties to sue, so petitioners' rule would equally limit the Sherman Act's application in criminal cases.

Second, "comity" and related doctrines are not presented here. In any event, petitioners have merely demonstrated the existence of *overlapping* jurisdictional regimes. Such overlaps are common, however, and do not preclude the exercise of U.S. jurisdiction. Of note, in contrast to *Hartford Fire*, there is not even an arguable conflict here between enforcement of the Sherman Act and any foreign regulatory regime, for cartels are universally condemned. But aggressive application of the Sherman Act remains necessary because current *enforcement* overseas is too lax to protect U.S. interests. Those nations that have anti-cartel laws but do not enforce them do not present comity concerns at all, since there is no substantive conflict of law and no risk of overlapping enforcement. Finally, it is Congress's job to account for changes in the international enforcement environment.

ARGUMENT

This case principally presents the question whether the "jurisdictional bar" of the FTAIA (Pet. Br. 42) limits the scope of the Sherman Act to instances in which the plaintiff's own claim arises from an anti-competitive conspiracy's effect on U.S. com-

commerce. It does *not* present the separate question whether, if the Sherman Act applies to respondents' claims and respondents have standing to sue, the U.S. courts should opt not to *exercise* jurisdiction to decide the claim. RESTATEMENT (THIRD) OF FOREIGN RELATIONS § 402 cmt. d (1987) (“[A]state may *exercise* jurisdiction based on effects in the state, when the effect or intended effect is substantial and the *exercise* of jurisdiction is reasonable under § 403.”) (emphases added). No argument was made below that the court should pretermitt this litigation based on comity, conflict of laws, or *forum non conveniens*. Thus, just as in *Hartford Fire*, this Court “need not decide” whether a court “should ever decline to exercise such jurisdiction on grounds of international comity.” 509 U.S. at 798. Such concerns “come into play, if at all, only after a court has determined that the acts complained of are subject to Sherman Act jurisdiction.” *Id.* at 797 n.24 (citing *Mannington Mills, Inc. v. Congoleum Corp.*, 595 F.2d 1287, 1298 (CA3 1979), which found jurisdiction, then remanded for consideration whether to exercise jurisdiction). See also Pet. C.A. Br. 41 n.16 (explaining that question presented by this case “*is different* from the question[] of ‘comity’” (emphasis added)).³

Petitioners rightly note that the U.S. antitrust laws are intended to protect U.S. interests (Br. 8), but they seek a radical shift in the test for determining whether those interests are sufficiently implicated to trigger the Sherman Act’s proscriptions. Petitioners focus on the antitrust laws’ application to “transactions,” a term that appears fifty-seven times in petitioners’ brief, and zero times in the Sherman Act, the Clayton Act, and the FTAIA. In fact, it is settled that “the essence of any violation of Section 1 is the illegal agreement itself – rather than the overt

³ In *Hartford Fire*, this Court rejected an attempt to incorporate concerns for the “reasonableness” of exercising jurisdiction into the definition of the scope of the Sherman Act. The Court held that Congress determined the “reasonable” scope of the antitrust laws when it codified the rule that the Sherman Act extends to overseas conduct with a substantial U.S. effect. 509 U.S. at 796-97 & nn.22-24.

acts performed in furtherance of it.” *Summit Health, Ltd. v. Pinhas*, 500 U.S. 322, 330-31 (1991).⁴

Furthermore, “it is well established by now that the Sherman Act applies to foreign conduct that was meant to produce and did in fact produce some substantial effect in the United States.” *Hartford Fire*, 509 U.S. at 796.⁵ This “effects” doctrine, first articulated by Judge Learned Hand in *United States v. Aluminum Co. of America (Alcoa)*, 148 F.2d 416, 444 (CA2 1945), was “pioneered” for just this type of case: “Off-shore cartels (*paradigmatically*) could be regulated by the U.S. antitrust laws if the cartel members intended to restrain commerce into the United States and their cartel had effects in the United States.” Eleanor M. Fox, *International Antitrust and the Doha Dome*, 43 VA. J. INT’L L. 911, 916 (2003) (emphasis added). Indeed, “one of the [Sherman Act’s] express goals * * * was to combat the trusts and cartels which, as Senator Sherman put it, were ‘imported from abroad.’” *Foreign Trade Antitrust Improvements Act: Hearings on H.R. 2326 Before the Subcomm. on Monopolies and Commercial Law of the House Comm. on the Judiciary*, 97th Cong. 42 (1981) (Prof. James A. Rahl) (Hearings on H.R. 2326).

Purporting to describe “every case where this Court has applied U.S. antitrust laws to foreign activity” (Br. 11), petitioners actually omit the three principal precedents addressing worldwide cartel activity. *United States v. American Tobacco Co.* confronted the “division of the world’s business” in tobacco through “contracts (executed in England).” 221 U.S. at 182, 172. This Court held that the Sherman Act prohibited “the assailed combination in all its aspects * * * including the foreign corporations in so far as by the contracts made by them they became coöperators in the combination.” *Id.* at 184. *United States*

⁴ Sherman Act jurisdiction mirrors the principle that, if a conspiracy has a sufficient nexus to this country, U.S. law applies even if *all* overt acts in furtherance thereof were committed overseas. See, e.g., *United States v. Wright-Barker*, 784 F.2d 161, 168 (CA3 1986) (citing cases).

⁵ See also RESTATEMENT § 402(1)(c) (“a state has jurisdiction to prescribe law with respect to * * * conduct outside its territory that has or is intended to have substantial effects within its territory”).

v. *National Lead Co.*, 332 U.S. 319, 348 (1947), held unlawful foreign agreements underlying the international titanium cartel. *Timken Roller Bearing Co. v. United States*, 341 U.S. 593 (1951), affirmed an injunction against a conspiracy “to restrain interstate and foreign commerce by eliminating competition in the manufacture and sale of antifriction bearings in the markets of the world,” including through “agreements providing for a territorial division of the world markets.” *Id.* at 595. And indeed, “not a single one of the 248 foreign commerce antitrust actions brought by the Justice Department through May 1973 was dismissed for lack of subject matter jurisdiction.” Barry E. Hawk, *Special Defenses and Issues*, 50 ANTITRUST L.J. 559, 560 (1981).⁶

The Sherman Act unquestionably renders petitioners’ cartel unlawful under the effects test reaffirmed in *Hartford Fire*. With respect to all but one of the more than one dozen vitamins controlled by the cartel, the U.S. is the world’s largest market, averaging 28% of all worldwide sales. Petitioners’ cartel “affect[ed] billions of dollars of U.S. commerce and last[ed] for almost a decade.” Belinda A. Barnett, Sr. Counsel to the Ass’t

⁶ When this Court held that the Sherman Act does not apply, it was because the defendants’ overseas conduct was *not* integrally related to anti-competitive effects in this country. A plaintiff may not merely assert the existence of a “global” conspiracy or “global” market but must, as here, be prepared to prove that the effects of the defendants’ activities here and abroad are intertwined. In *Matsushita Electrical Industries v. Zenith Radio Corp.*, 475 U.S. 574 (1986), U.S. electronics manufacturers alleged that Japanese companies conspired to raise prices in Japan, using the profits to subsidize predatory pricing in the U.S. This Court reaffirmed that the Sherman Act “reach[es] conduct outside our borders * * * when the conduct has an effect on American commerce.” *Id.* at 582-83 n.6. The Court held that the plaintiffs were accordingly required to prove that the “alleged cartelization of the Japanese market” caused “artificially depressed [prices] in the United States.” *Ibid.* But the plaintiffs lacked such proof, and thus could not “recover antitrust damages based *solely* on an alleged cartelization of the Japanese market, because American antitrust laws do not regulate the competitive conditions of other nations’ economies.” *Id.* at 582 (emphases added). Petitioners quote only the *end* of this statement without acknowledging its context. Br. 11.

A.G., Antitrust Div., Speech of Nov. 30, 2000, at 2-3. As petitioners conceded below, “there is no real dispute that the vitamin companies’ conduct had ‘a direct, substantial, and reasonably foreseeable effect’ on U.S. commerce.” Pet. App. 9a.

So petitioners have no choice but to seek a dramatic change in the law. They ask this Court to restrict the Sherman Act to particular claims that arise from an effect on U.S. commerce. With respect to cartels in particular, petitioners’ rule would effectively limit the Sherman Act to transactions that occur *in* U.S. commerce. See Br. 33 (“the location of individual ‘transactions’ [is] the controlling consideration for jurisdiction”). The Sherman Act’s application to an anti-competitive worldwide cartel would for the first time be broken down transaction by transaction. In this brief, we demonstrate beyond peradventure that Congress did not intend to adopt this departure from the settled effects test.

I. Because Global Cartels’ Domestic And Foreign Effects Are Inextricably Intertwined, Respondents Prevail Even Under Petitioners’ Construction of The FTAIA And Foreign Plaintiffs’ Claims Against Such Cartels Furthermore Directly Advance U.S. Interests.

As we demonstrate in the remainder of this brief, petitioners’ arguments as to the scope of the Sherman Act are wrong. But even if petitioners were right on the law, their arguments would rest on two propositions that are simply wrong as a matter of basic economics: (i) that the effects of their cartel on U.S. commerce were irrelevant to respondents’ injuries; and (ii) as such, the U.S. has no interest in deterring petitioners’ conduct. The root of the error of both propositions is petitioners’ failure to acknowledge that they were cartelizing a global market, not several geographically distinct markets. This premise – critical to their depiction of respondents’ injuries as taking place in a “foreign market” and thus unrelated to the cartel’s impact on the U.S. – is false, and without it, petitioners’ arguments collapse.

This Part corrects petitioners’ error, demonstrating that (A) the market for bulk vitamins is global; (B) the effects of the cartel on U.S. commerce gave rise to the claims of overseas pur-

chasers such as respondents; and (C) U.S. interests are advanced by recognizing the claims of all the cartel's victims.

A. The Market for Bulk Vitamins Is a Global Market.

Petitioners' brief rests entirely on the assumption that the bulk vitamins market is geographically divided, such that there is a distinct "U.S. market." See, *e.g.*, Br. 8, 40-41. This "U.S. market" is a fiction. Rather, there is a single, global market for bulk vitamins, which are fungible commodities bought and sold wherever the best price is available. Because transportation costs are minimal, purchasers can secure, and producers will deliver, supplies from whatever region of the world offers the best price.⁷

Respondents' complaint alleges that petitioners, who comprise essentially the entire worldwide production capacity for bulk vitamins, cartelized this "global market." J.A. 55.⁸ Tracking the government's indictment of petitioners – under which they were prosecuted for the operation of their "worldwide" cartel "in the United States and elsewhere" (see *supra* at 1) – the complaint explains that the petitioners agreed to "fix, increase, and maintain the price and allocate the volume" for vitamins in "the United States and elsewhere." J.A. 35. As cartel participants admitted in documents disclosed in a vitamins trial, petitioners rigorously implemented "a proposal for the global and regional allocation of sales volumes among the companies."

⁷ We are advised that Professor John M. Connor and others are submitting an *amicus curiae* brief detailing the features of the global vitamins market.

⁸ The complaint's allegations not only must be taken as true at the motion to dismiss stage, but they comport with this Court's precedents on market definition. "[T]he relevant competitive market * * * is of course the area in which respondents and the other * * * producers effectively compete." *Tampa Elec. Co. v. Nashville Coal Co.*, 365 U.S. 320, 331-32 (1961). As Judge Posner explains, the relevant "market" is defined not by geographic boundaries, but by "the output of the suppliers to which a group of customers can turn for their requirements of a particular product." *United States v. Rockford Mem. Corp.*, 898 F.2d 1278, 1283 (CA7 1990) (citing *Tampa Electric*).

Animal Sci. Prods. v. Chinook Group, Misc. No. 99-197, MDL 1285 (TFH), Pl. Exh. G-12, at 1.⁹

B. The Effects Of Petitioners' Conduct On U.S. Commerce Gave Rise To Respondents' Claims.

Assuming *arguendo* that, as petitioners contend, Clause 2 of the FTAIA applies to this case *and* requires that the effect of the defendant's conduct give rise to the plaintiff's claim, respondents' claims meet that test. In a global market, the location of particular purchases is economically irrelevant: respondents' complaint is not merely directed at the sellers from whom they bought, nor at those sales transactions, but at the overall conspiracy that deprived them of the opportunity to purchase at competitive prices from *anyone*. As the D.C. Circuit recognized, respondents "claim that [they] were injured as a direct result of the increases in United States prices even though they bought vitamins abroad." Pet. App. 3a. Petitioners' maintenance of the cartel in the U.S. precluded overseas purchasers from purchasing vitamins in the U.S., or in their own countries from intermediaries who purchased here for resale abroad.

Indeed, petitioners entered into a worldwide conspiracy *precisely* to prevent their customers in one region from turning elsewhere to escape the cartel's super-competitive prices. See 1 VED P. NANDA & DAVID K. PANSIUS, LITIGATION OF INTERNATIONAL DISPUTES IN U.S. COURTS § 5.13, at 213 (2003) (describing the "interdependence of the foreign and U.S. injured parties in * * * *Empagran*" because "the success of the global restraint" depended on cartelizing all national markets). As respondents argued in the district court, "prices in the United States were integrally interconnected with the prices outside of the United States. Pricing inside reflected pricing outside. * * * There was

⁹ For example, petitioners' market division scheme included an agreement that a principal vitamins supplier would "exit[] North America by July 1993 or sooner." *Id.*, Pl. Exh. 120. See also *id.*, Pl. Exhs. 80, 84, 108, 140, 153 (charts and maps of allocated sales). Petitioners also purchased a U.S. producer's overproduction "to keep [that producer] from disrupting * * * markets outside of the United States" (*id.* Pl. Exh. G-12, at 37); and endeavored to buy out manufacturers that did not participate in the cartel (see, *e.g.*, *id.*, Pl. Exh. G-12, at 7).

a unitary world market where virtually all purchasers * * * were considered fungible, and an injury in one market caused an injury in every other segment of that market.” C.A. J.A. 72.

Indisputably, had respondents attempted to purchase vitamins from cartel members in the U.S. at competitive prices, this suit would be proper. But overseas purchasers cannot be expected to take such a futile step; petitioners’ cartel commitments were the equivalent of placing out a sign in the United States declaring, “Sales to foreign purchasers prohibited.”

Petitioners’ conspiracy in the U.S. caused respondents’ injury in another sense: if the conspiracy had not extended to the U.S., it would have collapsed worldwide. It is well established that if not prevented, arbitrage will destroy a price-fixing cartel or at least severely limit its profits. As a consequence of “the resale by the low-price purchasers to the purchasers to whom the seller charges a high price” abroad, petitioners “would have no sales at [the higher price].” RICHARD A. POSNER, *ANTITRUST LAW* 83 (2d ed. 2001). Given the central role of the U.S. economy in world trade, “including the United States in a price-fixing conspiracy is necessary to generate monopoly profits.” *Den Norske Stats Oljeselskap AS v. Heeremac v.o.f.*, 241 F.3d 420, 435 (CA5 2001) (Higginbotham, J., dissenting).

Thus, even on petitioners’ construction of the FTAIA, requiring that the U.S. effects “give rise to” the *plaintiff’s* claim, the statute does not bar respondents’ claims. The phrase “gives rise to” in Clause 2 requires causation, but not that the plaintiff be injured *in* U.S. commerce. See U.S. Br. 14 n.3 (conceding this point); cf. *United States Indus./Fed. Sheet Metal v. Director*, 455 U.S. 608, 615 (1982) (language “arising out of” simply imposes a causation requirement). Here, the anti-competitive effects of petitioners’ worldwide cartel on the United States are a “but for” cause of respondents’ injuries; absent those effects, petitioners could have escaped cartel-dictated prices by purchasing from U.S. suppliers or from intermediaries who did. Nor is this causation “indirect and remote.” *Contra* Pet. Br. 41. To the contrary, respondents’ injuries are a completely foreseeable effect of petitioners’ conduct with respect to the United States – indeed, respondents’ inability to make lower-priced purchases in

the United States was the *intended* consequence of that conduct, not some unpredictable incident of it. Thus, even on the reading *most* favorable to petitioners – requiring that the U.S. effects be both a factual and a proximate cause of the plaintiff’s own injury – respondents would still prevail.¹⁰

C. U.S. Interests Are Directly Advanced By Recognizing The Claims Of All Victims Of An Integrated Cartel That Operates In The United States.

As Judge Higginbotham has explained, given the integrated nature of global markets, claims of foreign cartel victims “serve a single function: the protection of United States commerce.” *Den Norske*, 241 F.3d at 438-39 (dissenting opinion). Indeed, foreign purchasers are, in cartel cases like this one, essentially the *only* enforcers of the antitrust laws with respect to the cartel’s unlawful activities abroad. If a U.S. vitamin manufacturer had sought to compete abroad against the cartel’s members, it could unquestionably have sued petitioners under the Sherman Act (see, e.g., *Zenith Radio Corp. v. Hazeltine Research, Inc.*, 395 U.S. 100, 124-25 (1969); *Cont’l Ore Co. v. Union Carbide & Carbon Corp.*, 370 U.S. 690, 700, 704 (1962)), but because petitioners cartelized all bulk vitamins suppliers, all of the U.S. companies that could have been *competitors* are in fact *co-conspirators*. And suits by U.S. purchasers alone cannot deter cartels because they cannot force them to dis-

¹⁰ Proximate cause is probably not required, however. In various other contexts, courts have refused to infer such a test from similar language requiring that a plaintiff’s claim “arise” from a particular cause. See, e.g., *SFH, Inc. v. Millard Refrigerated Servs.*, 339 F.3d 738, 743 (CA8 2003) (only “but for” cause required); *Hamilton v. United Healthcare of La.*, 310 F.3d 385, 391 (CA5 2002) (“arising out of” means “incident to, or having connection with”); *Williams v. Imhoff*, 203 F.3d 758, 765-66 (CA10 2000) (“arising out of” means “‘originating from,’ ‘growing out of,’ or ‘flowing from,’” and does not require proximate cause); *Ballard v. Savage*, 65 F.3d 1485, 1500 (CA9 1995) (applying “but for” test to determine if plaintiff’s claim arises from contacts with the forum for personal jurisdiction purposes); *Lanier v. Am. Bd. of Endodontics*, 843 F.2d 901, 909 (CA6 1988) (“arising from” means “made possible” by or “lies ‘in the wake’ of” (quoting CA7 cases)).

gorge their overseas profits. Petitioners' position would thus "change[] the calculus of risk for rational cartel participants in a way that significantly decreases the law's deterrent effect on international cartels." Ronald R. Davis, *International Cartel and Monopolization Cases Expose a Gap in Foreign Trade Antitrust Improvements Act*, ANTITRUST, Summer 2001, at 53.

Specifically, the deterrent value of foreign purchasers' claims furthers U.S. interests in three respects. First, just as foreign consumers benefit when civil liability deters the closure of the U.S. market, U.S. consumers benefit directly when the overseas activities of an integrated, worldwide cartel are deterred. See *supra* at 11. Had petitioners fixed prices only in this country, U.S. purchasers could have obtained vitamins at competitive prices, either directly from abroad or from arbitrageurs. And had petitioners' market allocation scheme not kept certain suppliers out of the U.S. market, U.S. consumers would have benefited from lower-cost foreign supplies. Thus, petitioners engage in "semantic * * * gamesmanship" in characterizing their cartel as involving "a 'foreign conspiracy' * * * separate from 'a U.S. conspiracy'"; "but for the alleged foreign anticompetitive activity, it would have been impossible, given the globalized nature of the relevant markets, to impose an anticompetitive overcharge in the United States." Davis, *supra*, at 53, 54.

Second, deterring cartel activity abroad prevents cartels from emerging and accelerates their collapse, both to the benefit of U.S. consumers. Had petitioners' agreement not extended worldwide, its profits would have been severely limited by arbitrage. The availability of vitamins for export at competitive prices from overseas would have precluded super-competitive pricing anywhere else in the world, including the U.S. Indeed, when several Chinese suppliers, who were not cartel participants, began selling certain bulk vitamins in the global market in the mid-1990s, the cartel-set prices collapsed broadly. JOHN M. CONNOR, *GLOBAL PRICE FIXING* 293, 325 (2001).

Third, imposing liability for *all* of a worldwide cartel's activities prevents the participants from using their illegal overseas profits to subsidize the risk of liability in this country. In *Pfizer*,

this Court refused to bar foreign plaintiffs' claims and thereby "lessen the deterrent effect of treble damages":

If foreign plaintiffs were not permitted to seek a remedy for their antitrust injuries, persons doing business both in this country and abroad might be tempted to enter into anticompetitive conspiracies affecting American consumers in the expectation that the illegal profits they could safely export abroad would offset any liability to plaintiffs at home. If, on the other hand, potential antitrust violators must take into account the full costs of their conduct, American consumers are benefited by the maximum deterrent effect of treble damages upon all potential violators.

434 U.S. at 315. This Court rejected the defendants' argument (echoed by petitioners) that the antitrust laws protect Americans, a contention that "confuses the *ultimate purposes* of the antitrust laws with the question of *who can invoke* their remedies." *Ibid* (emphases added). See also *infra* at 32 (discussing FTAIA legislative history embracing *Pfizer's* rationale).¹¹

The added deterrent value provided by foreign purchasers' claims is vital in the context of a global cartel. Petitioners have recently paid approximately \$5 billion in criminal and civil sanctions, a sum that not only is significantly lower than the approximately \$10 billion in profits that the cartel realized during the 1990s, but is dwarfed by the present value of those profits.

Even that comparison overstates the deterrent value of the liability imposed on petitioners, *who were caught*. Adequate deterrence requires monetary liability that not only removes all illegal profits, but also reflects the probability that the wrongdoers might not have been caught. RICHARD A. POSNER, ECO-

¹¹ Petitioners' assertion that the plaintiffs in *Pfizer* purchased goods in the U.S. export market, not overseas (Br. 37), not only is "not clear" as a factual matter (SPENCER WEBER WALLER, ANTITRUST AND AMERICAN BUSINESS ABROAD § 9:9, at 9-25 (3d ed. 1997)), but also is a distinction without a difference. The location of the transaction often reflects happenstance; it says nothing about where its anti-competitive effects will be felt. Not surprisingly, this Court's opinion in *Pfizer* "betrayed no interest in minutiae, such as the geographic situs of transfer of title." *Davis, supra*, at 53, 54.

NOMIC ANALYSIS OF THE LAW 77-78 (1st ed. 1972). The available data on purely domestic cases “estimate[s] the probability of successful government prosecution of a price-fixing conspiracy in the United States to be, at most, between 13 and 17 percent.” Wouter P.J. Wils, *Does the Effective Enforcement of Articles 81 and 82 EC Require Not Only Fines on Undertakings But Also Individual Penalties, In Particular Imprisonment?* 13 (2001). International cartels are even more difficult to uncover, given their extraordinary sophistication, the fact that their activities often occur abroad, and the availability of national boundaries as a “cover” for the absence of international competition. See James M. Griffin, Dep. Ass’t A.G., Speech of Apr. 6, 2000.

Moreover, because a cartel cannot be sustained elsewhere if the U.S. market is competitive, effective deterrence requires that a cartel face punishment in the U.S. sufficient to offset its profits everywhere. See Harry First, *Evolving Toward What? The Development of International Antitrust*, in *THE FUTURE OF TRANSNATIONAL ANTITRUST LAW* 47 n.91 (Josef Drexler ed., 2003).¹²

3. Given the foregoing, petitioners’ argument that the United States has no interest in compensating foreign purchasers (Br. 35-36) is sleight of hand, for “the goal of sanctioning cartel conduct is *general deterrence*, *i.e.*, to deter others from engaging in the offending conduct.” James M. Griffin, Dep. Ass’t A.G., Speech of May 2002, at 6 (emphasis added). Congress adopted the Clayton Act’s civil damage remedy, in particular, to “enlist private plaintiffs in the work of detecting, punishing, and thereby deterring wrongdoing.” Phillip Areeda, *Antitrust Violations Without Damage Recoveries*, 89 HARV. L. REV. 1127, 1127 (1976). That remedy enhances deterrence in two ways: by increasing the probability of detection by creating an incentive for private litigants to uncover cartels; and by increasing the penalty upon detection.

¹² For the reasons detailed in the text, the view that the antitrust laws should not be read “to apply United States law to a transaction whose relation to the United States” is “minimal” (1A AREEDA ET AL., *supra*, ¶ 273c4 n.25 (2003 Supp.)) does not undercut the specific basis for finding jurisdiction over worldwide cartels.

There is “no dispute that cartel activity will not be deterred if the potential penalties are perceived by firms and their executives as outweighed by the potential rewards.” Scott D. Hammond, Dir. of Crim. Enf., D.O.J. Antitrust Div., Speech of Sept. 12, 2000, at 4. Petitioners’ hard core price-fixing in an unregulated market – “the supreme evil of antitrust” (*Verizon Communications, Inc. v. Law Offices of Curtis V. Trinko*, 124 S. Ct. 872, 879 (2004)) – calls for the most severe sanction. Congress did not intend the protection of U.S. interests to “depend on the uncertainties of foreign antitrust enforcement.” Pet. App. 33a. Further, even accounting for other nations’ anti-cartel enforcement mechanisms, it is clear that, as the OECD has recently concluded, “larger sanctions are required to achieve effective deterrence.” OECD, *HARD CORE CARTELS 3* (2002). Economic studies have calculated the “optimal fine” for deterrence purposes as at least “187% of the *commerce affected* by the cartel,” not merely the monopoly profits, such that “actual fines imposed were found to be less than 1% of the level necessary to deter cartel conduct. While fines have increased significantly [since then,] they are not now and never will be *anywhere near* the optimal fine level established by those studies.” James Griffin, Dep. Ass’t A.G., Speech of May 2002, 6-7 (emphasis added).¹³

The need for greater sanctions in part reflects the fact that foreign anti-cartel provisions are rarely enforced. Although “more than 90 countries now have antitrust laws, and almost all of these laws have anti-cartel provisions,” “[h]aving laws is not enough; they must be enforced.” William J. Kolasky, Dep. Ass’t A.G., Speech of Jan. 25, 2002. As the government’s principal modern study on international antitrust enforcement recently concluded, “[O]verall anticartel enforcement levels around the world *remain fairly low outside the United States*.” Int’l Comp. Pol’y Adv. Comm., Final Rep’t to the A.G. 186 (2000) (DOJ ICPAC Final Report) (emphasis added).¹⁴

¹³ We are advised that Joseph Stiglitz, Nobel Laureate and former World Bank Chief Economist, is submitting an *amicus curiae* brief demonstrating that worldwide cartels are seriously under-deterred.

¹⁴ A principal gap in cartel enforcement results from the refusal of national governments to enforce competition laws against resident

This case illustrates the point dramatically. Petitioners report that they have been subject to governmental actions by four competition authorities (“the European Union, Canada, Australia, and Korea”) and private actions in seven nations (“Canada, the United Kingdom, Germany, Belgium, and the Netherlands,” as well as “Australia and New Zealand”). Br. 4. Yet the cartel inflicted injuries in countries the world over.

Furthermore, the deterrent effect of foreign civil liability is minimal; civil suits against cartels in other countries have been largely unsuccessful. For example, although petitioners tout European enforcement, the Deputy Head of the EC Directorate General for Competition very recently confirmed that there has long been “limited private enforcement of EC competition rules.” Donncadh Woods, Paper of Feb. 20, 2004, at 3, 5.¹⁵ And even when private damages are awarded, “[t]he published cases

corporations. “Cartels continue to be a way of life in many parts of the world, impeding economic performance, promoting inequality, impoverishing consumers, and thereby providing fuel for those who oppose globalization and free market ideals.” William J. Kolasky, Dep. Ass’t A.G., Speech of Jan. 25, 2002, at 2. Cartels, “which seem to be quite frequent and to affect a number of countries,” “create a competition problem in foreign countries” whose “competition laws and policies in the countries in which they take place are usually *powerless* to curb them. Indeed, the jurisdiction of domestic competition authorities is usually limited to practices which affect competition in their own country.” Frédéric Jenny, Chairman, OECD Competition Law and Pol’y Comm., *Globalization, Competition and Trade Policy: Convergence, Divergence and Cooperation*, in *COMPETITION POLICY IN THE GLOBAL TRADING SYSTEM* 295, 306 (Clifford A. Jones & Mitsuo Matsushita eds., 2002).

¹⁵ For example, in England “there has been *one* successful action * * *, against the snooker world governing body”; “[i]n Italy there does not appear to have been *any* successful damages actions”; and “in Germany the only [successful] action [was] a declaratory action and no damages were awarded.” Donncadh Woods, Paper of Feb. 20, 2004, at 17 (emphases added). A German court recently “held that purchasers of cement at cartel prices could not claim damages *unless they had been individually targeted* by a market-sharing cartel.” *Id.* at 10 (citing *Max Boegl Bauunternehmung v. Hanson Germany*, Judgment of the Berlin Landgericht of 27 June 2003 (emphasis added)).

that have reached a decision in Europe suggest that damages awarded by national courts are modest in value.” *Id.* at 6.¹⁶

II. The FTAIA’s Jurisdictional Limitation Does Not Apply To Conduct Involving Import Commerce And Thus Does Not Apply To Worldwide Cartels.

Even if this Court did not accept our argument that respondents’ claims arose from the U.S. effects of petitioners’ conduct, respondents would still prevail because the premise of petitioners’ brief – that the FTAIA applies to this case – is wrong. In fact, the FTAIA does not apply to worldwide cartels, which are not limited to U.S. export commerce. See Resp. C.A. Br. 17. Congress did not take the illogical step, contrary to U.S. interests, of narrowing the Sherman Act’s application to cartels’ overseas activities in public and private enforcement actions.

A. The FTAIA Limits The Scope Of The Sherman Act Solely In Cases Involving Only U.S. Export Commerce.

1. The FTAIA was enacted as Title IV of the Export Trading Company Act of 1982. Congress expressly declared: “[T]he purpose of this Act is to increase United States exports of products,” including “by modifying the application of the antitrust laws to certain export trade” in the FTAIA. Pub. L. No. 97-290, § 102(b), 96 Stat. 1233, 1234 (1982). “Every single congressional finding relates to the importance of export business and the need to encourage export activity by American business.” *Den Norske*, 241 F.3d at 433 (Higginbotham, J., dissenting).

Two features make clear that the FTAIA promotes U.S. exports without *otherwise* narrowing the Sherman Act’s reach. First, the provision that includes Clauses 1 and 2, and thereby defines the scope of the Sherman Act, is limited by its introductory language to conduct involving foreign commerce “*other than* import trade or import commerce” (emphasis added). This provision was intended to replace the courts’ varying “expression[s] of the proper test for determining” jurisdiction in export

¹⁶ Nor could the existence of foreign antitrust regimes have informed the Congress that enacted the FTAIA; in 1982, “few countries had antitrust laws and fewer still enforced them.” Charles A. James, Ass’t A.G., Speech of Oct. 17, 2001, at 2.

cases (App., *infra*, at 4a) and thereby “create more certainty in the application of antitrust laws for those people who are about to engage in export trade activities” (Sherman E. Unger, *The Role of the Commerce Department, in THE EXPORT TRADING COMPANY ACT OF 1982* 11, 12 (Joseph P. Griffin ed., 1982)).

As this Court has already recognized, this critical introductory language – which petitioners omit (see Br. 3, 15) – means that the FTAIA’s requirements apply only to “conduct involving foreign trade or commerce, *other than import trade or import commerce.*” *Hartford Fire*, 509 U.S. at 796 n.23 (emphasis added). “The FTAIA was intended to exempt from the Sherman Act *export* transactions that did not injure the United States economy.” *Ibid.* The FTAIA’s statutory limitation, in sum, “applies to *export* trade.” 1A AREEDA ET AL., *supra*, ¶ 273c4 (emphasis in original). Accord RESTATEMENT § 415 cmt. a (“Congress has limited the application of the antitrust laws where they would affect United States export trade only.”).¹⁷

Second, Congress effectuated its intent to further the interests of exporters in the FTAIA’s proviso, which states:

If sections 1 to 7 of this title [the Sherman Act] apply to such conduct only because of the operation of paragraph (1)(B), then sections 1 to 7 of this title shall apply to such conduct only for injury to export business in the United States.

15 U.S.C. 6a. Cases governed by “paragraph (1)(B)” – which we will call “export cases” – affect U.S. commerce only with respect to “export trade or export commerce with foreign na-

¹⁷ By contrast, if Congress had intended the FTAIA to provide a universal standard for international antitrust actions, it would have neither included the statute’s introductory limitations nor limited its application only to *Sherman Act* claims. “It had been proposed that the standard of ‘direct, substantial, and reasonably foreseeable effect’ set out in the [FTAIA] should be applied to all types of commerce of the United States, including import and domestic commerce, and that the amendments apply also to the Clayton Act (dealing with mergers and acquisitions); the suggestions were not accepted by Congress.” RESTATEMENT § 415, rptrs. notes (emphasis added).

tions, of a person engaged in such trade or commerce in the United States.” *Id.* § 6a(1)(B).

The proviso limits standing in export cases by “preclud[ing] suits by foreign purchasers of U.S. exports.” Pet. Br. 19. The effect of the proviso is that “[f]oreign plaintiffs complaining of injuries sustained as a result of such combination of exporters would, in effect, *lack standing* under the Sherman Act.” RESTATEMENT § 415, rptrs. notes (emphasis added). The proviso’s restriction on standing notably does *not* apply to non-export cases, like this one, which are instead governed by paragraph (1)(A) and thus involve conduct that has a sufficient effect on “trade or commerce which is not trade or commerce with foreign nations, or on import trade or import commerce with foreign nations.” 15 U.S.C. 6a(1)(A). Indeed, the legislative history makes that very point. “Under current law, foreign nationals located abroad may in certain circumstances recover under our antitrust laws. *H.R. 5235 does not change that*. But if the requisite effect is felt *only* with respect to our export commerce, then H.R. 5235 does limit who may recover to persons engaged in export trade or commerce ‘in the United States.’” 128 Cong. Rec. 18,953 (1982) (Rep. McClory) (emphases added).

2. This case implicates neither the text of the FTAIA nor its purpose. And cartels, by restricting where participants may sell, *harm* exporters by foreclosing U.S. export opportunities.

In enacting the FTAIA to promote U.S. exports, Congress did not change the long-settled rule that the Sherman Act governs the domestic and foreign activities of cartels affecting the U.S.: “[*o*ff course, [the FTAIA] was *not* intended to cover the situation of a foreign cartel targeting United States markets.” 1A AREEDA ET AL., *supra*, ¶ 272i n.69 (emphases added). “Importantly, the [FTAIA] is not intended to affect jurisdiction over foreign conduct affecting *imports* into the United States. The Sherman Act’s application to United States and foreign participation in international *cartels* remains unchanged, as the House Report expressly recognizes.” Barry E. Hawk, *International Antitrust Policy and the 1982 Acts*, 51 FORDHAM L. REV. 201, 220 (1982) (emphases added). “*It could not be clearer* that the FTAIA serves to exempt exporting from antitrust scrutiny, not to

limit the liability of participants in transnational conspiracies that affect United States commerce.” *Den Norske*, 241 F.3d at 433 (Higginbotham, J., dissenting) (emphasis added).

The government’s Antitrust Enforcement Guidelines for International Operations expressly state that cartels like petitioners’ “Vitamins, Inc.” are not subject to the FTAIA. The Guidelines declare that conduct implicating foreign commerce is subject to one of two jurisdictional tests: (i) *Hartford Fire*’s rule that “the Sherman Act applies to foreign conduct that was meant to produce and did in fact produce some substantial effect in the United States”; or (ii) the FTAIA standard. U.S. D.O.J., *Antitrust Enforcement Guidelines for International Operations* § 3.11 (1995). The Guidelines explain that, because the FTAIA applies only “to foreign commerce *other than imports*,” it does *not* apply to cartels of “foreign companies that produce a product in various foreign countries” and “make substantial sales into the United States.” *Ibid.* (emphasis added). So long as the cartel engages in U.S. *import transactions*, jurisdiction over the *entire cartel* “is clear under the general principles of antitrust law expressed most recently in *Hartford Fire*,” because the facts “demonstrate actual and intended participation in U.S. commerce.” *Ibid.* By contrast, the FTAIA *would* apply when there are *no* direct sales to the U.S., *i.e.*, “in cases in which a cartel of foreign enterprises * * * reaches the U.S. market through any mechanism that goes beyond direct sales, such as the use of an unrelated intermediary.” *Id.* § 3.12.

The same conclusion follows from the version of the Guidelines in effect at the time Congress enacted the FTAIA. Congress intended the FTAIA’s jurisdictional provision to function as “a simple and straightforward clarification of existing American law and the Department of Justice enforcement standards.” App., *infra*, 5a. At that time, the 1977 Guidelines provided that Sherman Act jurisdiction extends to cartels without regard to where particular activities in furtherance of the cartel occurred. U.S. D.O.J., *Antitrust Guide for International Operations*, Case L, “Dealing With A Cartel” (Jan. 26, 1977). As described by the then-Deputy Assistant Attorney General for Antitrust, the position of the United States accordingly was “*strongly* that the ap-

plication of the antitrust laws to *foreign transactions* is *essential* to effective domestic enforcement.” John H. Shenefield, *The Perspective of the U.S. Department of Justice*, in PERSPECTIVES ON THE EXTRATERRITORIAL APPLICATION OF U.S. ANTITRUST AND OTHER LAWS 12, 24 (Joseph P. Griffin ed., 1979) (emphases added).

B. The Authorities Cited By Petitioners Actually Support Respondents’ Reading Of The FTAIA.

In contrast to this overwhelming evidence of the limited aegis of the FTAIA, petitioners muster four quotations from scholars ostensibly indicating that Congress intended to eliminate the claims of purchasers in overseas markets. But each of those quotations actually addresses the FTAIA’s proviso on *export* commerce, *not* its provision defining the Sherman Act’s scope.

First, petitioners quote the Areeda antitrust treatise as stating that “a foreign consumer whose only injury is felt entirely in his foreign country cannot [sue].” Br. 14 (brackets in Pet. Br.). In fact, the full quote states:

The *final quoted sentence* [of the FTAIA] is designed to make clear that a foreign firm *operating an export business* in the United States continues to be protected by the antitrust laws with respect to that business but not with respect to its operations outside the United States. Thus, although the exporter can sue with respect to the injured *export business*, a foreign consumer whose only injury is felt entirely in his foreign country cannot.

1A AREEDA ET AL., *supra*, ¶ 272h (emphases added).

Petitioners next quote a law review article to the effect that “foreign consumers need not be protected by the U.S. antitrust laws.” Br. 35-36. In fact, the full quote states:

Similarly, Atwood’s suggestion that foreign consumers need not be protected by the U.S. antitrust laws has been largely enacted into law, in *Title IV’s provision that only those involved in U.S. export business may complain of restraints on U.S. exports*.

David Gill, *Review of Antitrust and American Business Abroad*, 77 AM. J. INT’L L. 679, 781 (1983) (emphasis added).

Petitioners next quote an international antitrust treatise as stating that “[a]ntitrust injury suffered in foreign markets is excluded.” Br. 36. In fact, the full quote states:

The purpose and thrust of the FTAIA have been discussed above. Antitrust injury suffered in foreign markets is excluded from the scope of the Sherman and Federal Trade Commission Acts *unless it involves injury to a U.S. exporter*. Therefore, a foreign company claiming injury in one or more foreign markets *resulting from restraints of trade on the part of U.S. exporters* has no U.S. antitrust cause of action.

MARK R. JOELSON, AN INTERNATIONAL ANTITRUST PRIMER 52 (2001) (emphases added). The “discuss[ion] above” to which the author refers explains that the FTAIA “provid[es] a definition of the jurisdictional reach of the Sherman and FTC Acts *in the realm of export trade*.” *Id.* at 51 (emphasis added).

Petitioners finally quote another treatise as stating that the FTAIA “exclude[s] claims for [injuries] incurred only in foreign markets.” Br. 36 (second alteration in Pet. Br.). In fact, this quotation appears in the treatise’s chapter on “Export Commerce,” and specifically addresses the FTAIA’s “limitation of standing *to foreclosed U.S. exporters*.” 1 HAWK, *supra*, at 182.2-3 (Supp. 1996-1) (emphasis added). The full quote then states with respect to such export claims:

[The FTAIA] affects only jurisdictional rules and standing in the limited sense to exclude claims for [injury] incurred only in foreign markets. Substantive rules concerning antitrust injury and antitrust standing generally were not intended to be affected by Title IV. The House Report states as an example that the mere fact that *an exporter* may be financially harmed by the challenged conduct does not necessarily mean that it has sustained antitrust injury. Thus there may be no antitrust injury where harm is only to an individual firm (*exporter*) and there is no harm to competition.

Ibid (emphases added). The treatise author manifestly does not agree with petitioners. See *id.* at 177-78 (concluding that “Sherman Act jurisdiction over international cartels that affect imports and harm domestic competition remains unchanged”);

id. at 292 n.79 (“The 1982 amendments to the Sherman and FTC Acts were not intended to change their jurisdictional reach over international cartels.”).

III. Congress Inserted Clause 2 Merely To Ensure That The Covered Foreign Conduct Must Have An *Anti-Competitive Impact On Domestic Commerce To Be Actionable Under The Sherman Act.*

Even if the FTAIA applies to this case, Clause 2 does not require that the U.S. effects give rise to the plaintiff’s claim. Rather, it requires only that the challenged conduct’s effect on U.S. commerce be *anti-competitive*.

At the time the FTAIA was enacted (several years before this Court’s decision in *Matsushita*), there was “great confusion over whether the [defendants’ conduct] must in some way *adversely* affect the commerce involved.” James A. Rahl, *American Antitrust and Foreign Operations*, 8 CORNELL INT’L L.J. 1, 7 (1974). Congress resolved that confusion by adopting Clause 2 to codify the Second Circuit’s holding in *National Bank of Canada v. Interbank Card Ass’n*, 666 F.2d 6 (1981), that only *anti-competitive* effects on U.S. commerce are actionable. Accord *Kruman*, 284 F.3d at 399-400; *Den Norske*, 241 F.3d at 432 n.36 (Higginbotham, J., dissenting). As one of the principal House sponsors, Representative McClory, explained:

Another point which might be misunderstood regarding the standard of [the FTAIA] is the nature of the effect. Clearly, our exports create jobs and increase profits in the United States and thus have a beneficial impact on our economy. But this effect does not satisfy the standard of [the FTAIA]. * * * For what is needed is an effect in the United States, either in its domestic or its export commerce, which *gives rise to a claim under the antitrust laws*, as known today or as hereafter amended. Thus a beneficial effect or an adverse effect is, as such, insufficient. It must be an antitrust effect.

128 Cong. Rec. 18,953 (1982) (emphasis added).

Indeed, in the wake of the FTAIA’s passage, the consensus view was that Congress adopted Clause 2 simply to codify the

National Bank of Canada rule. Petitioners' assertion that "[f]ollowing enactment of the FTAIA, scholars and enforcement officials understood the amendment to preclude recovery for foreign injury" (Br. 35) is simply wrong:

- The government has for decades taken the view that Clause 2 merely adopts the *National Bank of Canada* rule.¹⁸
- Every antitrust treatise agrees. *E.g.*, 1A AREEDA ET AL., *supra*, ¶ 272h2 n.49 (under Clause 2, "the effects must be 'of the type that the antitrust laws prohibit'").¹⁹
- Every contemporaneous law review commentator agreed.²⁰
For the following reasons, this consensus view is correct.

¹⁸ See, *e.g.*, Donald Zarin, Office of Gen. Counsel, Dep't of Commerce, *The Export Trading Company Act: Reducing Antitrust Uncertainty in Export Trade*, 17 GEO. WASH. J. INT'L L. & ECON. 297, 313-14 (1983) ("In addition to requiring a direct, substantial, and reasonably foreseeable effect, title IV requires, as a jurisdictional element, that the effect give rise to a claim under the Sherman or FTC Acts. *This language* apparently is intended to ensure that an anticompetitive effect exist as a condition precedent to the assertion of jurisdiction." (emphases added)); Charles S. Stark, Chief, Foreign Commerce Section, U.S. D.O.J., Speech of Dec. 5, 1983, at 20-21 ("Title IV was intended not merely to clarify the quantum of domestic impact required to support antitrust jurisdiction, but the kind of impact. According to the Committee, 'the domestic "effect" that may serve as the predicate for antitrust jurisdiction under the bill must be of the type that the antitrust laws prohibit.' The remainder of the discussion in the report, and its reference to the *National Bank of Canada* case, make it clear that the effect on U.S. commerce has to be an anticompetitive effect.").

¹⁹ See also 1 WALLER, *supra*, § 9.7, at 9-12 to -13 (Supp. 2003); 1 HAWK, *supra*, at 179 (1996-1 Supp.); 1 WILBUR L. FUGATE, FOREIGN COMMERCE AND THE ANTITRUST LAWS § 2.14, at 106 (5th ed. 1996).

²⁰ *E.g.*, John F. Bruce & John C. Pierce, *Understanding the Export Trading Company Act and Using (Or Avoiding) Its Antitrust Exemptions*, 38 BUS. LAW. 975, 986-87 (1983); Barry E. Hawk, *International Antitrust Policy and the 1982 Acts: The Continuing Need for Reassessment*, 51 FORDHAM L. REV. 201, 223 (1982); John H. Shenefield, *Thoughts on Extraterritorial Application of the United States Antitrust Laws*, 52 FORDHAM L. REV. 350, 365 & n.85 (1983); A. Paul Victor & John G. Chou, *United States Antitrust Jurisdiction Over Overseas Disputes After Title IV of the 1982 Export Trading Company Act and Timberlane*, 10 FORDHAM INT'L L.J. 1, 14 (1986).

A. The Drafting History, Text, And Structure Of The FTAIA Confirm Congress’s Intent To Adopt The *National Bank of Canada* Rule.

1. Clause 2’s drafting history illuminates the statutory language. The “problem” addressed by Clauses 1 and 2 was the “possible ambiguity in the precise legal standard” under prior case law – specifically, “the *quantum* and *nature* of the effects required to create jurisdiction.” App., *infra*, 9a (emphases added). As originally proposed, the FTAIA addressed only “quantum,” requiring a “direct, substantial, and reasonably foreseeable effect” on U.S. commerce. Foreign Trade Antitrust Improvements Act, H.R. 5235, 97th Cong. § 7(1) (1982). Contrary to petitioners’ assertion that such an effect “would, virtually by definition, give rise to ‘a claim’ by *someone*” (Br. 20), the A.B.A. explained that the original bill “ignore[d] whether conduct has an adverse effect on competition,” such that “conduct which has an anticompetitive effect which impinges only on defendants located in foreign nations and which also has a neutral or procompetitve domestic effect would be subject to the antitrust laws.” Hearings on H.R. 2326, *supra*, at 259.

In response to the A.B.A.’s point, Congress added Clause 2. App., *infra*, 19a. Quoting the A.B.A.’s comments and citing *National Bank of Canada*, the House Report explains that

the domestic “effect” that may serve as the predicate for antitrust jurisdiction under the bill must be of the type that the antitrust laws prohibit. For example, a plaintiff would not be able to establish United States antitrust jurisdiction merely by proving a *beneficial* effect within the United States, such as increased profitability of some other company or increased employment, when the plaintiff’s damage claim is based on an extraterritorial effect on him of a different kind.

Ibid (emphasis in original). The Report subsequently reiterates that, under the bill as revised, “the proscriptions of the Sherman Act do not apply to *export or purely foreign commerce* unless the conduct has a direct, substantial and reasonably foreseeable *anticompetitive* effect on domestic or import commerce, or a domestic export opportunity.” *Id.* 23a (emphases added).

In response to the A.B.A.’s comments, Clause 2 was initially revised to require that the effect on U.S. commerce be “the basis of the violation alleged under this Act.” H.R. 5235, 97th Cong. § 7(2) (1982), *reprinted at App., infra*, 3a. Precisely because that language might be misread in the way petitioners now propose, it was further revised. As explained by Congressman Rodino (the author of the bill and revision), the Committee “added th[e] language” of Clause 2 simply “to make it absolutely clear that the basis of American antitrust jurisdiction has to be a domestic *anticompetitive* effect.” *Id.* 29a (emphasis in original). The final language enacted into law – that the effect on U.S. commerce must “give rise to a claim” – was adopted to *reject* any “suggest[ion] that an effect, rather than conduct, is the basis for a violation.” *Ibid.* Petitioners, of course, press *precisely* the construction that the statute was revised to reject: “that the effect” on U.S. commerce, “rather than conduct” (*i.e.*, petitioners’ conspiracy), “is the basis for a violation” of the Sherman Act.

Moreover, Congress rejected proposals offered by business groups that indeed would have prohibited suits by persons not injured as a result of the effect on U.S. commerce.²¹ These proposals sought to provide “antitrust liability only to those persons injured within the United States.” Hearings on H.R. 2326, *supra*, at 109 (statement of Martin F. Connor, General Electric Co.). Congress did not indicate any solicitude for that view,

²¹ See *The Foreign Trade Antitrust Improvements Act: Hearings on S. 795 Before the Comm. on the Judiciary*, 97th Cong. 130 (1981) (Business Roundtable) (proposing: “If conduct involving trade or commerce with foreign nations does directly, substantially, and foreseeably restrain trade or commerce within the United States, then the parties engaging in such conduct shall be liable *only for any injury so occurring within the United States* by reason of such restraints.” (emphasis added)); Hearings on H.R. 2326, *supra*, at 39-40 (General Motors Corp.) (proposing: “This Act shall not apply to conduct involving trade or commerce with any foreign nation unless, and *only to the extent that*, such conduct has a direct, substantial and foreseeable effect on trade or commerce within the United States or has the direct, substantial and foreseeable effect of excluding a domestic person from trade or commerce with such foreign nation.” (emphasis added)).

other than in the proviso, which *did* narrow foreign purchasers' standing in *export* cases.

2. The FTAIA's *structure* refutes petitioners' transaction-by-transaction approach to Sherman Act jurisdiction as well. Clause 1 limits the Sherman Act's application by reference to "conduct." The courts of appeals are unanimous that the term "conduct" "refers to any conduct that would violate sections 1 to 7 of the Sherman Act absent the FTAIA." *Kruman*, 284 F.3d at 398. Accord Pet. App. 9a. In a Section 1 case, the defendants' "conduct" is – as the government concedes – "their conspiracy to fix prices and allocate markets" (U.S. Br. 14), not isolated sales transactions. "The illegal act in this case was not the *imposition* of high prices but the *formation of the agreement to fix prices.*" *Kruman*, 284 F.3d at 398 (emphasis added).

Clauses 1 and 2 work in conjunction; the latter defines the nature of the U.S. effect required by the former. Clause 2 contains no suggestion that Congress intended it nonetheless to have a very different focus: not on the defendant's conspiracy but instead on particular sales transactions. Given this structure, Clause 2 is most naturally read as addressing the same issue as Clause 1 – *viz.*, determining whether the Sherman Act proscribes the defendant's *conspiracy*. It is not naturally read to shift the jurisdictional inquiry from the defendant's conduct to whether the particular claim before the Court arises in U.S. commerce.

3. For three reasons, Clause 2's text confirms that Congress intended simply to adopt the *National Bank of Canada* rule.

First, Clause 2 refers to "a claim," which naturally means "any claim," and which contrasts with the requirement of the prior version of Clause 2 that Congress rejected, that the effect on U.S. commerce be "the basis for *the* violation." Petitioners' reading furthermore avowedly requires inserting the word "plaintiff" into the statute: "The indefinite article 'a' refers generically to 'a claim' *of the plaintiff—i.e.*, any claim that *the plaintiff* may have 'under the provisions of sections 1 to 7' of the Sherman Act." Pet. Br. 15 (emphasis added and omitted). Surely, if Congress had intended to adopt petitioners' reading, which significantly changes the longstanding approach to Sherman Act coverage, it would have used the phrase "give[]

rise to *the plaintiff's* claim.” *Kruman*, 284 F.3d at 400. Accord *Den Norske*, 241 F.3d at 432 (Higginbotham, J., dissenting).

Second, the introduction to the FTAIA provides that the Sherman Act “appl[ies]” to a conspiracy “unless,” rather than “to the extent that,” the conditions set forth in Clauses 1 and 2 are met. Petitioners acknowledge that their position “would subject the same ‘unitary’ conduct [*i.e.*, their conspiracy] to U.S. antitrust regulation in some cases and not in others, depending on whether the plaintiff’s claim arose from an injury to U.S. commerce or an injury to foreign commerce” (Br. 18-19), a result at odds with the plain text. Cf. *John Hancock Mut. Life Ins. Co. v. Harris Trust & Sav. Bank*, 510 U.S. 86, 109 (1993) (contrasting “to the extent” with “if,” and concluding that conflating the two would be “at odds with the plain language”).

Third, Clause 2 refers to a “claim under sections 1 to 7 of this Act,” *i.e.*, a claim under the Sherman Act. If Congress intended to limit the right of particular parties to sue, it more naturally would have adopted a standing provision that, like the proviso, specifically addresses the plaintiff’s injury. See *Kruman*, 284 F.3d at 396. Alternatively, Congress would have amended, or at least referenced, the Clayton Act. A plaintiff “has standing to enforce § 1 by virtue of § 4 of the Clayton Act.” *Jefferson Parish Hosp. No. 1 v. Hyde*, 466 U.S. 2, 5 n.1 (1984). But “[t]he FTAIA did not amend the Clayton Act.” U.S. Br. 27.²²

²² For example, Congress amended the Clayton Act to codify this Court’s holding in *Pfizer* that foreign governments may sue under the Sherman Act, albeit for actual, not treble, damages. See 15 U.S.C. 15(b). And the several subsequent proposed bills that would have limited private plaintiffs’ standing and remedies in foreign commerce cases have each been framed as amendments to the Clayton Act. See Foreign Trade Antitrust Improvements Act of 1985, S. 397, 99th Cong. (1985); Foreign Trade Antitrust Improvements Act of 1986, S. 2164, 99th Cong. (1986); Foreign Trade Antitrust Improvements Act of 1989, S. 50, 101st Cong. (1989). The provisions of these other bills, unlike the FTAIA, would “not be applicable to actions instituted by United States antitrust enforcement agencies.” *Foreign Trade Antitrust Improvements Act of 1985: Hearings on S. 397 Before the Comm. on the Judiciary* (Hearings on S. 397), 99th Cong. 215 n.30 (1985) (A.B.A. Section of Antitrust Law Report on S. 397).

B. The House Report On Which Petitioners Rely Confirms That Congress Intended To Preserve The Claims Of Overseas Purchasers.

Petitioners' legislative history argument is premised on the FTAIA House Report. This reliance is misguided.

1. First, the House Report cannot provide sound support for petitioners' reading, because, when it was drafted, the *original* Clause 2 required that the effect on U.S. commerce be "the basis of the violation alleged." App., *infra*, 3a. In its *final* form, the statute instead requires simply that the U.S. effect "give rise to a claim" under the Sherman Act. As discussed in the preceding section, this language was adopted precisely to avoid the very implication petitioners now press. The final version clearly supports respondents' view, as indicated by floor statements of its sponsors after the change was made. See 128 Cong. Rec. 18,953 (1982) (Rep. Rodino) (FTAIA "retains full protection for *any person* injured by conduct that has a direct, substantial, and reasonably foreseeable *anticompetitive* effect on the domestic or import commerce of the United States" (emphases added)); *id.* at 27,385 (1982) (Rep. McClory) ("[FTAIA] place[s] jurisdictional limits on these laws so that they will not apply to our *export trade or to purely foreign trade* unless the conduct in question has a 'direct, substantial, and reasonably foreseeable' *anticompetitive* effect on our domestic commerce or on the commerce of exporters in the United States." (emphases added)).

2. Second, portions of the Report that petitioners omit demonstrate that even the *former* version of the statute did not support their view. First, the Report explains that "[a]ny major activities of an international cartel would likely have the requisite impact on United States commerce to trigger United States subject matter jurisdiction." App., *infra*, 22a. Petitioners' position also cannot be reconciled with the Report's explanation that Clause 2 was added in response to the A.B.A.'s comments to adopt the *National Bank of Canada* rule. See *supra* at 27. Nor is their construction consistent with the Report's repeated statements, starting with its very first sentence, that the FTAIA's sole purpose was "to promote American exports." App. *infra*, 4a.

Equally important, petitioners' position conflicts with the House Report's express adoption of *Pfizer's* deterrence rationale. See 434 U.S. at 308; see also *supra* at 15. According to the House Report, Congress determined to "preserv[e] the rights of foreign persons to sue under our laws when the conduct in question has a *substantial nexus* to this country" (not merely when it occurs *in* this country) because – as this "Court pointed out in *Pfizer*" – the failure to do so could "so limit the deterrent effect of United States antitrust law that defendants would continue to violate our laws, willingly risking the smaller amount of damages payable only to injured domestic persons." App., *infra*, 17a (emphasis added). Congress thereby embraced the conclusion "that *foreign plaintiffs* should have *full rights* under United States antitrust laws where the challenged conduct affected domestic and foreign markets indiscriminately." WALLER, *supra*, § 9:9, at 9-26 to 27 (emphasis added).

3. Even the three snippets petitioners extract from the House Report in context undermine their reading and demonstrate that not even the original version of Clause 2 required that the plaintiff's injury arise in U.S. commerce.

First, petitioners quote the Report's statement, tracking the bill's language at the time, that the domestic "'effect' providing the jurisdictional nexus" serves as "the basis for the injury alleged." Br. 34. But the full quote reads:

The Committee did not believe that the bill reported by the Subcommittee was intended to confer jurisdiction on injured foreign persons when that injury arose from *conduct with no anticompetitive effects in the domestic marketplace*. Consistent with this conclusion, the full Committee added language to the Sherman and FTC Act amendments to require that the "effect" providing the jurisdictional nexus must also be the basis for the injury alleged under the antitrust laws. *This does not, however, mean that the impact of the illegal conduct must be experienced by the injured party within the United States. As previously set forth, it is sufficient that the conduct providing the basis of the claim has had the requisite impact on the domestic or import commerce of the United States, or, in the case of conduct lack-*

ing such an impact, on an export opportunity of a person doing business in the United States.

App., *infra*, 19a-20a (emphases added). Thus, the Report’s reference to “the basis for the injury alleged” simply mimics the bill as it stood at the time, and “does not speak to the issue whether the particular plaintiff bringing the suit must have suffered an injury caused by the domestic anticompetitive effects of the conduct.” *Kruman*, 284 F.3d at 400 n.8.

Next, petitioners quote a reference to the protections afforded to foreign purchasers “in the domestic marketplace,” contending that this means foreign purchasers are only protected if their injuries are “sustained in U.S. commerce.” Br. 35 (quoting House Report at 10; App., *infra*, 17a). In fact, the full quote states:

The intent of the Sherman and FTC Act amendments in H.R. 5235 is to exempt from the antitrust laws conduct that does not have the requisite domestic effects. This test, however, *does not exclude all persons injured abroad* from recovering under the antitrust laws of the United States. A *course of conduct in the United States – e.g., price fixing not limited to the export market – would affect all purchasers of the target products or services, whether the purchaser is foreign or domestic. The conduct has the requisite effects within the United States, even if some purchasers take title abroad or suffer economic injury abroad.* Foreign purchasers should enjoy the protection of our antitrust laws in the domestic marketplace, just as our citizens do.

App., *infra*, 17a (emphases added and omitted and citations omitted). The Report’s reference to “the protection of our antitrust laws *in the domestic marketplace*” merely reflects the fact that the hypothetical being addressed by this passage concerns “[a] course of conduct *in the United States.*” The full quote cannot support petitioners’ inference that foreign plaintiffs are protected *only* “in the domestic marketplace” in other contexts – to the contrary, it makes clear that foreign plaintiffs are covered even if they “take title abroad or suffer economic injury abroad.”

Finally, petitioners repeatedly invoke the phrase “wholly foreign transactions” in isolation (Br. 13, 33, 40) to offer a meaning that the full text refutes. The full quote states:

A transaction between two foreign firms, even if American-owned, should not, merely by virtue of the American ownership, come within the reach of our antitrust laws. Such foreign transactions should, for purposes of this legislation, be treated in the same manner as export transactions—that is, there should be no American antitrust jurisdiction absent a direct, substantial and reasonably foreseeable effect on domestic commerce or a domestic competitor. The Committee amendment therefore deletes references to “export” trade, and substitutes phrases such as “other than import” trade. It is thus clear that wholly foreign transactions, as well as export transactions are covered by the amendment, but that import transactions are not.

Br. App. 16a (emphasis added). This passage explains why the drafters extended the FTAIA’s limitation on Sherman Act jurisdiction to “wholly foreign” commerce in addition to export commerce, distinguishing the Sherman Act’s application to import commerce. And the quote’s references to “transactions” means not individual retail *sales*, as petitioners suppose, but the *anticompetitive agreements* alleged to be unlawful. See *ibid* (citing as an example of a “wholly foreign transaction” the facts of *Pacific Seafarers, Inc. v. Pacific Far East Line, Inc.*, 404 F.2d 804 (CA DC 1968), in which two shippers entered into a conspiracy to exclude competitors). But in any event, the Report merely states that the FTAIA *applies* to wholly foreign transactions such that jurisdiction exists if Clauses 1 and 2 are satisfied, not (as petitioners would have it) that the FTAIA *excludes* them from the coverage of the Sherman Act.²³

²³ Petitioners’ drive-by constitutional challenges are equally meritless. Congress’s Foreign Commerce power extends to even wholly overseas conduct that is intended to affect, and does in fact affect, the U.S.; moreover, the scope of its commerce power turns on the *activity* regulated, not on which *plaintiffs* are challenging it. *Strassheim v. Daily*, 221 U.S. 280, 285 (1911). And not even petitioners’ novel due process claim would lie here, for due process is satisfied if the defen-

IV. As Direct Victims Of Petitioners’ Worldwide Cartel, Respondents Have Suffered “Antitrust Injury” And Have “Antitrust Standing.”

The question whether respondents satisfy the prudential “antitrust injury” and “antitrust standing” doctrines is entirely derivative of the question whether the Sherman Act applies to their claims. See *Den Norske*, 241 F.3d at 431 n.32. The anti-competitive conduct that is subject to the private right of action under the antitrust laws is co-extensive with the conduct that is subject to criminal prosecution. “As the courts have often noted, * * * the selfsame language of the Sherman Act provides for both criminal and civil sanctions, and for the full array of these penalties.” 2 AREEDA ET AL., *supra*, ¶ 303a. The Clayton Act, in conferring a right to sue upon “any person injured by reason of anything forbidden in the antitrust laws” (15 U.S.C. 15(a) (emphasis added)), manifestly does not contemplate that *no* person would have the right to remedy acts that are illegal under the Sherman Act. Rather, the antitrust injury and standing doctrines seek to enhance the deterrent effect of the antitrust laws by identifying efficient antitrust enforcers.

Overseas direct purchasers are the *only* enforcers of the antitrust laws who may bring a claim challenging the illegal overseas acts of a worldwide cartel: U.S. *indirect* purchasers were not directly injured by the conspirators’ sales, while all the U.S. *competitors* that otherwise might sue are, in fact, *co-conspirators*. Petitioners’ argument would, for the first time, convert doctrines intended to identify the most efficient enforcers of the antitrust laws into a rule forbidding *any* enforcers from challenging patently unlawful activity. Such a perverse result has no basis in either law or logic, and any meritorious concerns petitioners raise regarding the scope of this litigation are instead properly resolved through doctrines such as comity, conflict of laws, and *forum non conveniens* that, as we have discussed, are not now before this Court.

dants’ conduct had foreseeable effects on U.S. commerce. Lea Brilmayer & Charles Norchi, *Federal Extraterritoriality and Fifth Amendment Due Process*, 105 HARV. L. REV. 1217, 1245-48 (1992).

A. Respondents Have Antitrust Standing Even Under Petitioners' Proposed Standards.

This case does not present an appropriate occasion to decide whether existing standing doctrine should be modified as petitioners propose. First, for the reasons described in Part I, *supra*, respondents' claims do, in fact, arise from the effects of petitioners' cartel on U.S. commerce. In sum, petitioners' fixing of U.S. prices, as well as their global market-division scheme, were critical to maintaining the cartel overseas. Had petitioners *not* included the U.S. in their cartel, respondents would have been able to purchase vitamins at competitive prices, and the cartel would have collapsed due to arbitrage. Petitioners' activities in the U.S. are thus the direct cause of respondents' injuries.

Second, reiterating that the antitrust laws are intended to protect U.S. consumers, petitioners suggest that standing should be limited to those claims that will further U.S. interests. Br. 43-45. Petitioners continue to “confuse[] the ultimate purposes of the antitrust laws with the question of who can invoke their remedies. The fact that Congress' foremost concern in passing the antitrust laws was the protection of Americans does not mean that it intended to deny foreigners a remedy when they are injured by antitrust violations.” *Pfizer*, 434 U.S. at 314.

As we have explained, in the case of global cartels, foreign purchasers' claims further U.S. interests. When a cartel is operating simultaneously here and abroad, the United States will benefit directly from the destruction of the cartel elsewhere, as arbitrage will allow U.S. purchasers to escape super-competitive U.S. cartel prices. And indeed, claims by foreign purchasers prevent cartel activity in the U.S.: if a cartel in a global market cannot operate worldwide, it will collapse. Furthermore, as this Court concluded in *Pfizer*, claims by foreign purchasers deter cartels from subsidizing the risks of liability in this country with their profits abroad. See *supra* at 13-19.

Pfizer itself notably held that the foreign plaintiffs in that case suffered “antitrust injury” and had standing. 434 U.S. at 315. And *Pfizer*, when applied to cartels, necessarily means that persons injured here and abroad may sue. As the A.B.A.'s International Law Section wrote in its resolution supporting the

FTAIA, “Because the antitrust laws would be fully applicable to such conduct, a plaintiff would retain the right to recover all damages caused by the effects of the restrictive conduct; *whether those effects fell within or without the United States*. As a result, there would be no incentive for a firm to offset domestic liability for restraints impinging on domestic commerce by engaging in coordinated conduct abroad.” Hearings on H.R. 2326, *supra*, at 255 (emphasis added).

B. Petitioners’ Proposed Standing Rule Is Inconsistent With This Court’s Precedents And Congress’s Intent.

1. Respondents Satisfy The Settled Requirements For Antitrust Standing.

Petitioners contend that their standing rule can be derived from this Court’s statement in *Brunswick Corp. v. Pueblo Bowl-O-Mat, Inc.*, 429 U.S. 477, 489 (1977), that antitrust injury is injury “that flow[s] from that which makes defendants’ acts unlawful.” Br. 44. But as *Brunswick* and its progeny make clear, what makes actionable conduct “unlawful” is that it is anti-, not pro-, competitive; this Court has never suggested that standing turns on whether the injury arose from an effect on U.S. commerce. *Brunswick*, 429 U.S. at 489. See also, *e.g.*, *Atl. Richfield Co. v. USA Petro. Co.*, 495 U.S. 328, 338 (1990); *Cargill, Inc. v. Monfort*, 479 U.S. 104, 116 (1986). In this case, respondents unquestionably were injured by the anti-competitive effects of petitioners’ conduct – namely, the super-competitive prices imposed by the unlawful cartel.

Indeed, the most analogous precedents of this Court reject petitioners’ contention that a plaintiff’s injury must arise from an effect on U.S. commerce. Petitioners argue that “[r]espondents’ own injuries were not caused ‘by reason of’ an agreement in restraint of commerce ‘among’ the several states or ‘with’ foreign nations.” Br. 42 (quoting 15 U.S.C. 1). That is simply not correct: the agreement that injured respondents – petitioners’ *conspiracy* – indisputably operated in U.S. domestic and foreign commerce. There is no requirement that a plaintiff’s *injury itself* arise from an effect on U.S. commerce. The logical consequence of petitioners’ argument would be that a plaintiff’s injury must arise from an effect on inter-, rather than intra-, state com-

merce, for the Sherman Act applies only to agreements affecting the former. See 1A AREEDA ET AL., *supra*, ¶ 273b (noting that the effects test “is not different in principle” from the “‘affecting commerce’ test for domestic jurisdiction”). This Court has rejected any such suggestion, however, instead permitting claims arising from wholly *intrastate* injury so long as the challenged conduct *also* has substantial interstate effects. See, e.g., *Summit Health*, 500 U.S. at 330 (rejecting as irrelevant defendant’s contention that “there is no factual nexus between the restraint on [plaintiff’s local medical practice] and interstate commerce”); *McLain v. Real Estate Bd.*, 444 U.S. 232, 242, 246 (1980).

Petitioners also invoke the “antitrust standing” factors identified in *Associated General Contractors v. California State Council of Carpenters*, 459 U.S. 519, 543 (1983). At bottom, the question is whether the plaintiff is an efficient enforcer of the antitrust laws, or instead asserts an injury that is too remote from the unlawful conduct. Relevant considerations include the directness of the injury suffered; whether it is speculative; judicial manageability; and the potential for multiple recoveries. *Ibid.* These factors do not support eliminating the recognition of foreign direct purchasers’ non-speculative claims against a worldwide cartel, even if, as petitioners suggest, they may limit foreign claims in *other* international antitrust contexts. The United States thus seemingly concedes that respondents’ claims “suffer none of the defects mentioned in *Associated General Contractors*.” U.S. Br. 29 n.9.

When, as here, foreign and domestic customers suffer an identical injury from a single, integrated course of conduct, none of the *Associated General Contractors* considerations is implicated. Respondents’ claims are not “remote,” “indirect,” or “speculative.” See 459 U.S. at 543. And contrary to petitioners’ hyperbolic assertions, respondents’ claims present no prospect of an unmanageable drain on judicial resources. Respondents filed this suit as a companion case to the indistinguishable claims of plaintiffs who purchased vitamins for delivery in this country. The unlawful act – petitioners’ conspiracy – is precisely the same in both cases. The plaintiffs’ relationship to the petitioners – direct purchaser – is likewise identical. There is

furthermore a great overlap in the discovery to be undertaken; indeed, the overwhelming majority of the evidence necessary to establish the defendants' liability has already been collected. And in a cartel case such as this, respondents' claims require no special inquiry into foreign economic conditions or law, because the defendants engaged in "*per se* [antitrust violations]: market division, * * * consumer allocation, production limitations, and price fixing or price stabilization." 1 HAWK, *supra*, at 286 (Supp. 1996-1) (emphasis added).²⁴

All told, foreign purchasers have brought suit against only a half-dozen cartels.²⁵ Each paralleled a federal prosecution that found the defendants' conduct – here *and abroad* – unlawful. And these claims have generally proceeded in tandem with the pending "domestic" claims.

The subtext of petitioners' argument is instead that this case will involve a great *many* plaintiffs. See, *e.g.*, Br. 44. That, of course, is entirely petitioners' own doing. They engaged in a gigantic scheme to bilk their customers out of billions of dollars and now hope to minimize the resulting liability. As this Court indicated in *Pfizer*, it is precisely the grandness of an illegal scheme like petitioners' that requires the firm application of the jurisdiction conferred in the Sherman Act. It is not a viable argument that *this case* is unmanageable, for some amount of

²⁴ Compare Br. 27-28 (hypothesizing *other*, non-cartel cases involving "novel claims," disputes over "whether agreements directed at different countries constitute multiple narrow conspiracies or one broad conspiracy," and claims "where the challenged restraint is not a 'per se' violation [unlike] price-fixing"); U.S. Br. 23 (hypothesizing non-cartel claims involving disputes over "whether the challenged foreign conduct was part of some global conspiracy, whether that global conspiracy had the requisite effects on domestic commerce, and whether some third person was injured in United States commerce in such a way that gave rise to a claim").

²⁵ In addition to this case, *Kruman* (auction houses), and *Den Norske* (heavy-lift barges), respondents are aware of three other cartel cases: *Newco Trading Co. v. Ajinomoto Co., Inc. et al.*, No. 03-CV-8217 (S.D.N.Y.) (monosodium glutamate); *Latinoquimici-Amtex S.A. v. Akzo Nobel Chems. B.V.*, No. 03-CV-10312 (S.D.N.Y.) (sodium monochloroacetate); and *Ferromin Int'l Trade Corp. v. Ucar Int'l, Inc.*, C.A. No. 99-693 (E.D. Pa.) (graphite electrodes).

complex litigation is the inevitable consequence of the U.S.'s central role in an increasingly global economy, and established litigation devices such as class action procedures minimize the burden on our courts. This Court, in any event, has already concluded that manageability alone is not a ground for denying antitrust standing to persons, such as respondents, whose claims "promote the vigorous enforcement of the antitrust laws." *Kansas v. Utilicorp United Inc.*, 497 U.S. 199, 214 (1990).

Indeed, petitioners' antitrust standing argument would *unravel* the doctrines this Court has crafted to preserve judicial manageability and effective antitrust enforcement. Petitioners' sales injured indirect purchasers in the United States, *i.e.*, purchasers of finished products that were manufactured overseas using cartelized vitamins. "[V]itamins manufacturers sell most of their output in dry powder form, eventually to be used for human and animal nutritional purposes in a wide variety of products, from vitamin pills, to feed for chicken, beef, and fish, to nutritional enrichment in numerous food products." Harry First, *The Vitamins Case*, 68 ANTITRUST L.J. 711, 712 (2001). Those finished products necessarily bore higher prices, because the cartel inflated the costs those manufacturers incurred for an important ingredient.

Such U.S. indirect purchasers are currently prohibited from bringing claims on the theory that a more efficient enforcer exists: namely, the direct purchasers. *Illinois Brick Co. v. Illinois*, 431 U.S. 720, 737-38 (1977). But if foreign direct purchasers' claims were forbidden, the injury to U.S. indirect purchasers who buy from them would stand without remedy, permitting violators to "retain the fruits of their illegality." *Hanover Shoe, Inc. v. United Shoe Mach. Corp.*, 392 U.S. 481, 494 (1968). The resulting gap in the deterrent function of antitrust remedies could be filled only by a ruling that the *Illinois Brick* doctrine does not apply to indirect purchasers' claims if the direct purchasers are overseas. But *that* approach – which would permit U.S. indirect purchasers to bring claims – would be genuinely unmanageable,

requiring U.S. plaintiffs to prove the effects of an illegal cartel on each of the imported products they purchased.²⁶

2. Congress Declined To Adopt The Restriction On Standing That Petitioners Propose.

Petitioners' proposed standing rule mirrors their theory of FTAIA jurisdiction; as explained *supra*, however, Congress squarely rejected such an approach. This case thus does not present a gap that Congress has left this Court to fill by changing the law of antitrust standing. The right of persons injured overseas to sue under our antitrust laws is a question that Congress has carefully considered. And it would be nonsensical to conclude that Congress in the FTAIA decided to preserve Sherman Act jurisdiction over claims by foreign purchasers for injuries cartels cause overseas, but simultaneously intended to eliminate those claims on standing grounds.²⁷

a. Petitioners have not identified *any* pre-FTAIA decision of *any* court, and respondents are aware of none, holding that a person lacks standing merely because his injury did not arise from the effect of a Sherman Act violation on U.S. commerce. Instead, petitioners attempt to put the shoe on respondents' foot, asserting that, "[a]s of the time Congress enacted the FTAIA, no case had ever authorized claims arising from foreign transactions occurring wholly outside U.S. commerce." Br. 9. This assertion is wrong, for at the time Congress enacted the FTAIA, there had been several such cases.

²⁶ Petitioners' suggestion that this case presents a third-party, or "derivative," standing problem (Br. 15-16) is not correct. Respondents' claims are based solely on their *own* injuries. Nor would courts, to determine the existence of jurisdiction, be required to adjudicate the merits of some hypothetical third party's claims. As we showed in Part III, *supra*, the requirement that the conduct give rise to "a claim" simply limits the Sherman Act to conduct causing anti-competitive effects in the United States – effects petitioners concede.

²⁷ To be clear, standing is not coextensive with Sherman Act coverage. Many foreign purchasers' claims would be excluded by this Court's traditional antitrust standing and injury doctrines: *e.g.*, speculative claims, claims by foreign indirect purchasers, and claims not arising from the defendant's anticompetitive actions.

Indeed, petitioners *themselves* cite such a case, and acknowledge that it is discussed in the House Report. In *Industria Siciliana Asfalti, Bitumi, S.p.A. v. Exxon Research & Engineering Co.*, No. 75-5828-CSH, 1977 U.S. Dist. LEXIS 17851 (S.D.N.Y. Jan. 18, 1977) (cited in Br. 31 n.7 and House Report at 5 (App., *infra*, 9a)), the plaintiffs were permitted to pursue a claim for injury “confined to Italy” and arising from an Italian contract. The court explained that

the fact that the plaintiff’s injury in this case has materialized in a foreign country, and been borne by a foreign corporation which does not directly engage in import from or export to the United States, is not a sufficient ground upon which to deny it antitrust protection. * * * [T]he foreign plaintiff is not without standing to cite the deleterious domestic effects in support of his own antitrust complaint.

Id. at *30-*31. See also, *e.g.*, *Hunt v. Mobil Oil Corp.*, 550 F.2d 68 (CA2), cert. denied, 434 U.S. 984 (1977) (defendants conspired to prevent plaintiff, an oil producer in Libya, from securing Libyan government contracts); *Dominicus Americana Bohio v. Gulf & Western Indus., Inc.*, 473 F. Supp. 680 (S.D.N.Y. 1979) (plaintiffs, mostly foreign corporations alleging no U.S. injury, had standing to challenge defendants’ monopolization of tourist facilities in the Dominican Republic).²⁸

²⁸ Petitioners cite this Court’s decision in *Matsushita*, *supra*, as supposedly holding that “private plaintiffs challenging [a] multinational conspiracy can seek redress only for injuries that occur ‘in the American market.’” Br. 43 (quoting *Matsushita*, 475 U.S. at 584 n.7). In fact, the quoted phrase makes a factual, not legal, point: the plaintiffs in that case (U.S. electronics manufacturers) only claimed to suffer an antitrust injury “in the American market.” The Court held that plaintiffs were required to prove that defendants “conspired to price predatorily in the American market” because the other behavior that they alleged (including some conduct in Japan), although anti-competitive, did not harm them. 475 U.S. at 584 n.7. *Matsushita* thus imposed no geographic requirement for standing. To the contrary, had the plaintiffs competed in Japan and been harmed by defendant’s exclusionary behavior there, they clearly *would* have had standing, for they would have been injured in U.S. export commerce as a result of their inability to sell their goods abroad. See *Zenith*, 395 U.S. at 124-25.

b. Against the background of this case law, it is apparent that petitioners' point that "Congress made clear that it did 'not intend to alter existing concepts of antitrust injury or antitrust standing'" (Br. 42 (quoting House Report, at 11 (App., *infra*, 18a))) actually supports *respondents'* view: Congress preserved established law providing that foreign purchasers *could* sue for their overseas injuries. Congress expressly focused on the question of standing when it adopted the proviso, overruling cases that gave standing to foreign purchasers in cases involving only U.S. export commerce. The proviso's failure to cover non-export cases shows that Congress intended to preserve standing in such cases. Indeed, Congress *rejected* proposals that would have extended the proviso's limit on standing to non-export cases like this one. See *supra* at 28 & n.21.

After the FTAIA was enacted, Congress repeatedly revisited the same issue, and in each instance declined to change established standing law. Shortly after adopting the FTAIA, Congress amended the standing provision of the Clayton Act to codify this Court's holding in *Pfizer* that foreign governments may sue under the antitrust laws (albeit for single, not treble, damages). The amended statute imposed no limitation on where the injury must arise. 15 U.S.C. 15(b). And subsequently, Congress has considered the remedies available to private parties in international antitrust cases, but it has never even *considered* eliminating standing entirely for plaintiffs like respondents. And Congress has rejected even the more limited proposals.²⁹

²⁹ For example, the Foreign Trade Antitrust Improvements Act of 1985 would have amended the Clayton Act to require courts to apply the "jurisdictional rule of reason" in foreign competition cases. See Hearings on S. 397, *supra*. If a particular suit violated that standard, courts would have been required to award only single damages or, conceivably, dismiss the case. S. 397, *supra*, §§ 3, 4 (1985). Similar legislation was introduced in 1986 and 1989. S. 2164, Foreign Trade Antitrust Improvements Act of 1986, 99th Cong. (1986); S. 50, Foreign Trade Antitrust Improvements Act of 1989, 101st Cong. (1989). The Reagan Administration successfully *opposed* efforts to limit the treble-damages remedy in international cartel cases on the ground that such claims were essential to preserving the Sherman Act's deterrent effect. Hearings on S. 397, *supra*, at 22 (Charles F. Rule, Acting Ass't

V. The Other Arguments Of Petitioners' *Amici* Lack Merit.

Petitioners' *amici* finally urge this Court to narrowly construe the FTAIA for two reasons entirely extraneous to either the text or history of the statute: (i) to ensure the effectiveness of the government's leniency program; (ii) to preserve international comity. Both arguments lack merit.

A. The Government's Leniency Program Is Not A Justification for Misinterpreting the FTAIA.

The government asserts that permitting the claims of all cartel victims will discourage participation in its leniency program. U.S. Br. 19-21. This cannot inform this Court's construction of the FTAIA, for this leniency program has existed only "[s]ince 1993" (U.S. Br. 19), and thus could hardly have informed Congress's decisions respecting the FTAIA's scope more than a decade earlier. The government's contention is thus merely a bald policy overture, ungrounded in the FTAIA or any other statute. We address the matter briefly to show that for several reasons, the policy the government now espouses is a bad one.³⁰

First, Congress is addressing the government's concern, but in a much more targeted way than the government's blunderbuss proposal here. The Senate Judiciary Committee has favorably reported an Administration-sponsored bill, the Antitrust Criminal Penalty Enforcement and Reform Act of 2003, which will greatly increase the penalties for Sherman Act violations but limit plaintiffs to actual damages with respect to those *particular defendants* that participate in the leniency program. H.R. 1086, tit. II, § 213(a), 108th Cong. (2003). The government's proposal here, by contrast, is both under- and over-inclusive. It would fail to immunize companies participating in the leniency pro-

A.G.); *id.* at 306 (James C. Miller, FTC Chairman); *id.* at 40 (Abraham Sofaer, Legal Adviser, U.S. Dep't of State).

³⁰ The government's citation (U.S. Br. 21) to *United States v. Borden Co.*, 347 U.S. 514 (1954), for the proposition that Congress intended the government to be the principal antitrust enforcer is simply misleading, for it ignores this Court's *conclusion* in *Borden* that "private and public actions were designed to be cumulative, not mutually exclusive," such that both forms of antitrust enforcement "may proceed simultaneously or in disregard of each other." *Id.* at 519.

gram from treble-damage liability for harms to U.S. consumers. But it would immunize cartel participants who do *not* participate in the leniency program. And it equally impugns the *foreign* private remedies the government now touts. *E.g.*, U.S. Br. 25.

Second, the government's argument is self-destructive – if accepted, it would undermine the leniency program. Most important, as already discussed, the FTAIA defines the *scope* of the Sherman Act and, as such, applies equally to prosecutors. If petitioners' position were correct, cartel activity abroad would be immune even from *injunctive* relief in a criminal enforcement action by the government. The contrary assumption, underlying the government's entire brief, that Clause 2 merely governs the standing of private parties to sue (see, *e.g.*, U.S. Br. 8 (“The FTAIA governs whether a federal court may hear *a plaintiff's complaint* alleging violations of the Sherman Act.” (emphasis added)) is absolutely wrong. The FTAIA applies equally to “Sherman Act suits by the Department of Justice and private parties.” App., *infra*, 14a. Indeed, Congress enacted the FTAIA to “provide assurances against private plaintiff[s] successfully proposing different standards than those employed by the Department of Justice.” *Id.* 6a. See also S. CONF. REP. NO. 97-644, at 29-30 (1982) (FTAIA enacts “a jurisdictional threshold for enforcement actions”). When conduct does not satisfy the FTAIA's requirements, “private litigants have no right to recover damages under the Sherman Act, and the FTC and Justice Department are barred from bringing a civil or criminal action.” John H. Shenefield, *Thoughts on Extraterritorial Application of the United States Antitrust Laws*, 52 FORDHAM L. REV. 350, 364 (1983). Thus, by exempting foreign cartel participants from liability in the U.S., the government's position would actually weaken its own leniency program, as such participants would have less to fear from U.S. prosecutors and would be even less inclined to apply.³¹

³¹ Petitioners' reading of the FTAIA would equally undercut the deterrent value of the criminal fines imposed under U.S. law. Although petitioners' extensive presence in this country made it possible to base their fines on their domestic sales, the government has steadfastly maintained that “a court may consider the defendant's worldwide (U.S.

Furthermore, civil suits play a crucial role in cartel detection and deterrence. In this case, for example, “Class Plaintiffs uncovered the alleged conduct among bulk vitamins producers before the federal cooperation agreements became public and before any defendants confessed to their wrongdoing.” Order, *In re Vitamins Antitrust Litig.*, Misc. No. 99-197, at 5 (Feb. 18, 2004). The same holds true generally: “*Many more violations* are likely to be detected if private parties have an interest in doing so than if government agencies, with their meager budgets, shoulder the burden alone.” MIROW & MAURER, *supra*, at 226 (emphasis added). The government’s own experience shows that “cartel members did not fear detection by U.S. or foreign antitrust authorities. In fact, they literally laughed at the very idea of it.” Scott D. Hammond, Dir. Of Crim. Enf., Speech of Sept. 12, 2000, at 8. The government has seen “over and over” the “contempt and utter disregard that the members of the cartel typically have for antitrust enforcement.” James M. Griffin, Dep. Ass’t A.G., Speech of Apr. 6, 2000, at 6.³²

Third, the government has repeatedly rejected the very argument it advances here, maintaining that civil liability does not discourage participation in this program because reduced criminal exposure provides all the incentive that is needed. Applicants typically save hundreds of millions of dollars in fines (between \$800 million and \$2.1 billion for lead petitioner Hoffmann-La Roche, for example) and – perhaps most important – avoid jail time. See James M. Griffin, Speech of Aug. 12, 2003,

and foreign) sales in the calculation when the amount of U.S. commerce affected * * * understates * * * the impact of the defendant’s conduct on American businesses and consumers.” DOJ ICPAC Final Report, *supra*, at 169 n.24. But if petitioners’ reading were accepted, a cartel’s overseas activity would be *lawful* under the Sherman Act and therefore presumably could not form the basis of any criminal fine.

³² This case is a perfect illustration. The lead petitioner brazenly continued its central role in this cartel even after pleading guilty to participating in a worldwide citric acid cartel. “Instead of being deterred, top-level HLR executives orchestrated false statements to enforcement authorities, took steps to further conceal the firm’s illegal activities, and continued to lead the world’s other producers in a global cartel.” Hammond, Dir. of Crim. Enf., Speech of Sept. 12, 2000.

at 8; Scott D. Hammond, Dir. of Crim. Enf., Speech of Mar. 8, 2001, at 8; *Interview with* [Dep. Ass't A.G.] Gary Spratling, *supra*, at 11; Gary Spratling, *Cartel Roundtable, The Architects of Enforcement*, 6 GLOBAL COMPETITION REV. 25 (2003).

B. The Exercise Of Jurisdiction Over A Worldwide Cartel Does Not Offend Comity.

We explained *supra* at 6 that this case does not present the question whether this or any other international antitrust case should be dismissed on comity grounds, for comity was never invoked nor addressed in the lower courts. Although petitioners' *amici* press the issue, their arguments establish that this case raises *no* substantial issue of comity because – as petitioners effectively concede (Br. 23) – cartels are uniformly condemned by international competition laws. “For decades, there were vigorous disputes in international fora about whether it made sense to prohibit cartel behavior by private firms. That debate has been resolved, in this country and elsewhere.” R. Hewitt Pate, Acting Ass't A.G., Speech of May 16, 2003, at 2. For example, the U.N. Conference on Trade and Development and OECD condemn hard-core cartels. DOJ ICPAC Final Report, *supra*, 185.³³

For that reason, invocations of comity here are substantially weaker than those unsuccessfully advanced by the defendants in *Hartford Fire*. In that case, the defendants' conduct – which took place entirely in the U.K. – was “perfectly consistent with British law and policy” (509 U.S. at 799); on that basis, four Justices dissented (*id.* at 819-21 (Scalia, J., dissenting)). Here, by contrast, cartel activity is broadly condemned.

³³ Without elaboration, petitioners assert that in *McCulloch v. Sociedad Nacional de Marineos de Honduras*, 372 U.S. 10 (1963), *Romero v. International Terminal Operating Co.*, 358 U.S. 354 (1958), and *Lauritzen v. Larsen*, 345 U.S. 571 (1953), “differences in sovereign policies regarding available remedies prompted the Court to construe the federal statutes as inapplicable.” Br. 22. But these cases do not address differences in *remedies* for illegal conduct; rather, they address a concern specific to maritime law, namely the need to protect shippers from constantly changing *substantive legal obligations* as the ships pass through foreign waters. These cases simply apply the long-established rule that the law of a ship's flag state governs the legal duties of those aboard toward one another.

Petitioners' argument is furthermore surpassingly overbroad. Rather than allowing for the case-specific application of comity concerns, petitioners would redefine the scope of the Sherman Act *across the board* just because in *some* cases the antitrust laws apply to *some* activities simultaneously regulated by *some* other nations. Petitioners' jurisdictional exclusion would apply to U.S. defendants (including those in this case) no less than foreign ones, even though only the latter raise comity concerns. Furthermore, any comity concerns with respect to the great many states that have anti-cartel laws but do not enforce them (see *supra* at 17 & n.14) are overborne by the unprecedented and illogical gap in antitrust enforcement petitioners would create. Whatever the result under doctrines such as comity, conflict of laws, and *forum non conveniens* with respect to claims that involve sales in countries that provide effective class-based private rights of action, the ongoing emergence of competition policies overseas cannot be said to have broadly abrogated the settled "effects" principle as petitioners propose.

But even limited to its own terms, petitioners' argument merely demonstrates the existence of *overlapping* jurisdiction over their cartel – a common phenomenon – not a conflict that precludes exercising Sherman Act jurisdiction. "Exercise of jurisdiction by more than one state may be reasonable – for example, * * * when one state exercises jurisdiction over activity in its territory and the other on the basis of the effect of that activity in its territory * * *." RESTATEMENT § 403 cmt. d. The right to exercise jurisdiction is limited to one nation only in a narrow circumstance: "only when one state requires what another prohibits, or where compliance with the regulations of two states exercising jurisdiction consistently with this section is otherwise impossible." *Id.* § 403 cmt. e. Overlapping jurisdictional regimes are also a valuable tool for deterring cartel behavior: "multiple enforcers create a higher probability of detection, successful investigation, and a complete package of punishment that reflects the global effects of the unlawful conduct." Spencer Weber Waller, *Bringing Globalism Home: Lessons from Antitrust and Beyond*, 32 LOY. U. CHI. L.J. 113, 135-36 (2000).

With respect to this case specifically, the exercise of U.S. antitrust jurisdiction over petitioners' cartel is clearly reasonable and comports with comity. "Any agreement in restraint of United States trade that is made outside the United States, and any conduct or agreement in restraint of such trade that is carried out predominantly outside of the United States, are subject to the jurisdiction to prescribe of the United States, if a principal purpose of the conduct or agreement is to interfere with the commerce of the United States, and the agreement or conduct has some effect on that commerce." RESTATEMENT § 415(2). As noted, the United States purchases more bulk vitamins than any other nation. And in the parallel suits brought by domestic purchasers, petitioners have admitted to conducting numerous meetings in the United States in furtherance of their conspiracy.³⁴

Indeed, not only are cartels uniformly condemned in international law, but the U.S. "effects" principle has gained widespread acceptance in the cartel context. RESTATEMENT § 402, rptrs. notes ("This basis for jurisdiction is increasingly accepted for regulation of restrictive business practices, particularly in the European Community * * *"). "When there is the most blatant form of conspiracy in restraint of trade, a horizontal price-fixing agreement between competitors, the antitrust regimes of the world are united in the view that it does not matter that the smoke-filled rooms where the plots are hatched are abroad." Russell J. Weintraub, *Globalization's Effect on Antitrust Law*, 34 NEW ENG. L. REV. 27, 28 (1999). For example, E.U. officials may "recommend fines up to 10 percent of a violator's *global*

³⁴ That this case does not offend comity is also illustrated by the government's prosecution of petitioners for their conduct here and abroad. "In applying the principle of reasonableness, the exercise of *criminal* (as distinguished from civil) jurisdiction in relation to acts committed in another state may be perceived as *particularly* intrusive." RESTATEMENT § 403 rptrs. notes (emphases added); see also *id.* cmt. f. The fact that the U.S. government determined both that petitioners overseas activities fell within the scope of the Sherman Act (apparently recognizing the intertwined nature of the global vitamins market) and also that the exercise of jurisdiction over petitioners' cartel would not offend comity is thus a strong indication that this civil suit is equally appropriate.

annual sales in all its product lines.” CONNOR, *supra*, at 85 (emphasis added).

Also instructive is the British High Court’s decision in *Provimi v. Aventis Animal Nutrition SA*, [2003] E.C.C. 29. Appearing here as an *amicus*, the U.K. describes *Provimi* as a case in which “[p]ersons *injured* by the vitamin cartel *in the United Kingdom* were allowed to sue British subsidiaries in the UK courts for private damages.” U.K. Br. 4 (emphases added). In fact, as explained by the current Assistant Attorney General for Antitrust, the claims in *Provimi* were “made on behalf of a German subsidiary that purchased vitamins from a German subsidiary of one of the cartel members,” and the High Court “ruled that plaintiffs could sue a U.K. subsidiary of the defendant cartel member for the damages alleged to have been suffered in Germany, even though the damages relate to trade with the German subsidiary of the defendant.” Pate, Acting Ass’t A.G., Speech of May 16, 2003, at 13. And the Deputy Head of the E.C.’s Competition Directorate explains that “the English court, like the Court of Appeals for the District of Columbia Circuit [in this case], granted jurisdiction for an injury suffered *outside its territory*.” Woods, *supra*, at 8 (emphasis added).

The substance of the comity arguments advanced by petitioners’ *amici* is thus directed not at the exercise of Sherman Act jurisdiction over worldwide cartels, but instead at the extraterritorial exercise of jurisdiction over other forms of anti-competitive conduct abroad, such as monopolies, mergers, and allegations of unfair trade practices. See, e.g., Pet. Br. 23 (“Although price-fixing is widely proscribed, *other* commercial activities that may be prohibited under U.S. law may be permissible under foreign law.” (emphasis added)). In those other contexts, where international norms and standards differ, comity principles may have substantial force. They have none in the case of worldwide cartels, which are condemned in essentially every jurisdiction. RESTATEMENT § 415, cmt. e.

CONCLUSION

For the foregoing reasons, the judgment of the court of appeals should be affirmed.

Respectfully submitted,

Michael D. Hausfeld
Paul T. Gallagher
Brian A. Ratner
COHEN, MILSTEIN,
HAUSFELD & TOLL, P.L.L.C.
1100 New York Ave., N.W.
Suite 500, West Tower
Washington, DC 20005

Thomas C. Goldstein
(Counsel of Record)
Amy Howe
GOLDSTEIN & HOWE, P.C.
4607 Asbury Place, N.W.
Washington, DC 20016
(202) 237-7543

Michael H. Gottesman
600 New Jersey Ave., N.W.
Washington, DC 20001

March 15, 2004